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Shuxian Z. Sinks
(ABSTRACT)
Response adaptive designs intend to allocate more patients to better treatments with-
out undermining the validity and the integrity of the trial. The immediacy of the primary
response (e.g. deaths, remission) determines the efficiency of the response adaptive de-
sign, which often requires outcomes to be quickly or immediately observed. This presents
difficulties for survival studies, which may require long durations to observe the primary
endpoint. Therefore, we introduce auxiliary endpoints to assist the adaptation with the
primary endpoint, where an auxiliary endpoint is generally defined as any measurement
that is positively associated with the primary endpoint. Our proposed design (referred
to as bivariate adaptive design) is based on the classical response adaptive design frame-
work. The connection of auxiliary and primary endpoints is established through Bayesian
method. We extend parameter space from one dimension to two dimensions, say primary
and auxiliary efficacies, by implementing a conditional weigh function on the loss func-
tion of the design. The allocation ratio is updated at each stage by optimization of the
loss function subject to the information provided for both the auxiliary and primary
outcomes. We demonstrate several methods of joint modeling the auxiliary and primary
outcomes. Through simulation studies, we show that the bivariate adaptive design is
more effective in assigning patients to better treatments as compared with univariate
optimal and balanced designs. As hoped, this joint-approach also reduces the expected
number of patient failures and preserves the comparable power as compared with other
designs.
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Chapter 1
Introduction
1.1 What is adaptive design
Adaptive designs allow for the modification of clinical trials based on accumulating data,
without undermining the validity and the integrity of the trial (Chow et al., 2005). The
modifications include, but are not limited to: stopping a trial early due to safety, effi-
cacy or futility based on interim analysis, sample size reestimation, and dropping inferior
groups (Gallo et al., 2006). These designs are critical in the clinical development of new
drugs in early phases, which involves long-term commitments in time and economic costs.
The designs are flexible to be modified based on collected data, through such the modi-
fications and adaptations have to be thoughtfully planned in randomization designs.
Adaptive design can be categorized based on four different rules: randomization rule, sam-
pling rule, stopping rule, and decision rule (Mahajan and Gupta, 2010). Randomization
rule intends to allocate more patients to better treatment by changing the probabilities
of assigning patient in each arm. It consists of response-adaptive design and covariate-
adaptive allocation. The sampling rule defines how many patients will be sampled at
1
2the next stage to detect treatment difference. It includes sample-size reestimation and
drop-the-loser design. The stopping rule intends to stop the trial when efficacy or futility
of the treatment is obvious. It comprises group sequential design and adaptive treatment-
switching design. The decision rule refers to the changes different from the other three
rules, such as hypothesis-adaptive design, change the primary end-point design etc.
1.1.1 Response adaptive design
Response-adaptive designs are a common adaptive randomization procedure, which al-
lows modification of the allocation rate and schemes for placing more patients on the
better treatment based on patient responses. It may be used to allocate more patients to
a better treatment for Phase III clinical trials when the sample size is large. Thompson
(1933) has introduced the idea of assigning patients to the better treatment by adapting
the allocation rate, if there exits a preference between the two treatments. He also uses
bayes probabilities to judge between the rival two treatments, where non-informative pri-
ors are applied and their interval lie in the possible range (0, 1). Several response-adaptive
designs have subsequently been developed for binary responses in controlled clinical trials,
such as the play-the-winner rule, the randomized play-the-winner rule, the drop-the-loser
rule, optimal adaptive rule etc. Our response-adaptive design is an extension of the op-
timal response-adaptive design proposed by Rosenberger, Stallard, Ivanova, Harper and
Ricks (RSIHR) (Rosenberger et al., 2001). The optimal allocation rate changes in order
to meet certain objectives, such as to minimize number of patients to inferior treatment
or to maximize the power and ensure sufficient sample size to the trial. The sample size
is predetermined by the design according to the objectives, not resulting from an ad hoc
3basis. Neyman allocation maximizes the power of the test of comparing two binomial
probabilities, where its allocation rate of assigning to treatment A takes the form of
√
pAqA√
pAqA+
√
pBqB
, the ratio of standard deviations. Optimal response adaptive designs should
consider the statistical power and the number of patients assigned to inferior treatment.
Neyman allocation does not perform well out of ethical consideration when pA + pB > 1,
because it assigns more patient to the inferior treatment. However, RSIHR allocation
(called optimal allocation) minimizes the expected number of patient deaths (or treat-
ment failures) and maintains comparable statistical power as balanced randomization and
Neyman allocation. Its allocation rate, instead, takes the form of
√
pA√
pA+
√
pB
.
1.2 Motivations
Treatment success rates, pA and pB both are unknown parameters and estimated based
on the data. Therefore, the optimal procedure becomes effective when the data can be
rapidly collected and do not require long-term follow-up. Unfortunately, quick availabil-
ity of patient responses is one obstacle holding researchers from applying these methods
in practice. It is common that no observations are observed at the early stage of a clini-
cal trial. Then, the allocation rate will not be updated and stays at the specified initial
leading probability, which undermines the purpose of the design. Ultimately, the slow
adaptation due to slowly observed responses does not benefit the randomization. To al-
leviate this drawback, Rosenberger and Lachin (1993) suggested to adapt the allocation
ratio after groups of patients instead of after each individual patient. The solution is not
quite promising when the flow of enrollment is faster than the flow of data collection,
particularly when the primary outcome is delayed and rarely observed.
4We are motivated to introduce a response-adaptive allocation method that incorporates
auxiliary outcome, which is hopefully correlated with the primary outcome. This is dif-
ferent from biomarker-adaptive designs, where the adaptation merely depends on the
response of biomarker (eg. genomic markers). Also, the auxiliary endpoint is not a surro-
gate endpoint as defined by Prentice (1989) to directly substitute primary endpoint. The
auxiliary endpoint is defined as a response variable that can strengthen primary endpoint
analysis and frequently be observed (Fleming et al., 1994). Usually, we do not need to
make any additional assumptions on the auxiliary outcome to use it in the analysis. The
way of implementing the auxiliary outcome without ignoring the primary outcome in-
formation becomes critical to increase the flexibility of response-adaptive design on data
collection. The essence of response adaptive design clearly states a goal or objective to
minimize the total loss or failure of patients in each treatment group. Inspired by this
characteristic, we extend the parameter space to dimensions, say primary and auxiliary
efficacies, by implementing a conditional weight function to describe the loss. Bayesian
analysis naturally suits for this purpose, as it easily incorporates observed responses and
historical information about the parameters of interest in the adaptation.
Intuitively, there are two approaches to joint modeling auxiliary and primary outcomes
using Bayesian methods. One approach is to construct joint likelihood and have inde-
pendent priors for each parameter of interest. A bivariate binomial distribution would
be naturally chosen for the joint likelihood of two binomial random variables. Several bi-
variate binomial distributions have been formulated and studied in the literature. Aitken
and Gonin (1935) derived a bivariate binomial distribution with fixed equal marginals
and different binomial probabilities, where the equal marginals limits its application.
Hamdan (1972) derived a canonical form of bivariate binomial distribution with unequal
5marginals but equal binomial probabilities, however, it is not applicable for our scenario.
Marshall and Olkin (1985) discussed a bivariate binomial distribution based on a bivari-
ate Bernoulli distribution, where the distribution is originally found by Teicher (1954).
Hamdan and Jensen (1976) pointed out that this distribution is a bivariate binomial
under certain conditions and can be illustrated as the case when the marginals of a 2*2
contingency table are observed but the cell counts are not available. Unfortunately, these
distributions are in a complicated form and their properties have not been profoundly
studied.
An alternative approach is to have independent likelihoods for each outcome and construct
a joint prior for the parameters of interest. Therefore, we need a bivariate prior distri-
bution to describe the association of the parameters. In one dimensional cases, we know
that the beta distribution is the natural conjugate prior distribution for that binomial
likelihood. Extending to two dimensional cases, a bivariate beta distribution might be
an appropriate choice to consider. Gupta and Wong (1985) have studied three-parameter
and five-parameter bivariate beta distributions. The three-parameter distribution is a bi-
variate Dirichlet distribution and its correlation is always negative. However, our aim is
to find a bivariate distribution to model the positive correlation between two proportions.
The five-parameter bivariate beta distribution is a Morgenstern type (Morgenstern, 1956)
bivariate distribution. Unlike three-parameter distribution, it is not restricted to negative
correlations. Also, the extra parameters allow more flexibility in application. However,
it has been shown that the correlation of Morgenstern type bivariate distributions has a
small maximal range from −1
3
and 1
3
(Schucany et al., 1978). Olkin and Liu (2003) have
constructed a three-parameter distribution based on gamma distributions with desirable
properties. For instance, its expanded power series is related to the hypergeometric func-
6tion, and the density is positively likelihood ratio dependent.
The purpose of presenting the distribution is to have it server as prior on the support
0 ≤ xi ≤ 1 for positively correlated parameters of the binomial distribution. In this
trend, we want to construct a bayesian model where the association of the outcomes
is solely through that of the corresponding parameters, assuming the two outcomes are
independent given the parameters. This is the main model we will use during the entire
research.
1.3 Prospectus
In the next chapters, we aim to solve the following problems:
1.3.1 Ranges of correlations using three- and five-parameter bi-
variate beta models in case of informative prior specifica-
tion
Olkin and Liu have shown that the three-parameter bivariate distribution derived from
gamma distributions is quite flexible on positive correlation when the marginals are not
fixed. In bayesian analysis, we have it serve as the prior distribution for the correlated
binomial random variables, and prior information usually places on the marginals and
correlations. Therefore, the flexibility of the distribution with fixed marginals on corre-
lation is critical to the analysis. In this chapter, we compare the performance of Olkin
and Liu’s bivariate beta distribution and Morgenstern type bivariate beta distribution
on correlation when their marginals are fixed. We show that the correlation of Olkin
and Liu’s bivariate beta distribution with fixed marginals fails in a formulated bound-
7ary. Using analytic methods, it has been shown that the correlation boundary changes
corresponding to the marginals. Morgenstern type bivariate beta distributions with fixed
marginals are always restricted in range of [−1
3
, 1
3
]. For certain conditions, Olkin and
Liu’s bivariate beta distribution attains higher correlation than Morgenstern type bivari-
ate beta distribution. For the sake of a relatively flexible correlation range, we have
chosen the three-parameter bivariate beta distribution proposed by Olkin and Liu to be
the prior distribution for our bivariate adaptive desgin model, even though its correlation
has a limited range.
1.3.2 Response adaptive allocation using auxiliary and primary
outcomes for binary outcomes in case of the two treatment
groups
The bivariate optimal adaptive design framework is developed based on the optimal adap-
tive for binary outcomes (Rosenberger et al., 2001) in this chapter. We refer to the optimal
adaptive proposed by Rosenberger et al. as the univariate optimal adaptive design in the
following chapters. In order to implement the auxiliary outcome in the adaptation, we
assume that auxiliary and primary outcomes follow binomial distribution, and the pa-
rameters of these distributions are also random variables and jointly distributed in the
three-parameter bivariate beta distribution presented in Chapter 2. Also, we assume that
the correlation of auxiliary and primary outcomes is predetermined regardless of treat-
ment. Through some theoretical derivations, the bivariate optimal allocation depends
on the ratio of the expectations of posterior conditional distribution of the primary pa-
rameter given the auxiliary parameter for both treatment groups, where the expectations
8are related to the hypergeometric function. The univariate optimal design realizes the
minimization of expected number of patient failures. The bivariate optimal design mini-
mizes the risk of patient failures given auxiliary outcome information, which is different
from the goal of the univariate optimal desgin. We perform simulation study to com-
pare bivariate optimal adaptive designs to the univariate optimal adaptive and balanced
randomization designs, in terms of expected number of patient failures, allocation ratios,
power/error rate, and number of patients assigned to each treatment group. Then, we
also have discussed how the correlation of auxiliary and primary outcomes affects the
simulation results of the bivariate optimal adaptive design.
1.3.3 Applying copula method for constructing a bivariate dis-
tribution with beta marginals as prior distribution
We have noticed that the three-parameter bivariate beta distribution with fixed marginals
is limited in its range of correlation. In order to overcome this obstacle, we use copula
method to construct a bivariate distribution with beta marginal distributions as the prior
distribution for the proposed bivariate optimal adaptive design. Sklar (1973) has stated
that any multivariate joint distribution can be written as the combination of several
univariate marginal distributions and a copula function which describe the dependence
structure among random variables. Therefore, the copula method allows us to separately
model the dependence of two random binomial variables and their marginal distribu-
tions. In this chapter, we disccuss the simulation results of the bivariate optimal method
using copula-based prior and studied the performance of the adaptation using posterior
variance and sample variance in the procedure. Different copula functions suit different
9types of data, and two major copula functions are commonly used: elliptical copulas and
Archimedean copulas. We have simulated the bivariate optimal design using Gaussian
and Clayton copula-based prior distributions separately, which are representative of the
two major copulas. By the mean of changing the dependence parameter of the copula,
we intend to examine how the procedure is affected by the dependece of two random
variables.
Chapter 2
Ranges of Correlations using
Bivariate Beta Models for
Informative Prior Specification
(written as manuscript)
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2.1 Introduction
The beta distribution is a natural-conjugate prior for the binomial likelihood, where the
posterior expectation is a linear combination of data and prior parameters (Diaconis and
Ylvisaker, 1979). The constructed correlated binomial distribution is complicated and
not unique, because it can be formed from different directions to describe the association
of two binomial distribution (Biswas and Hwang, 2002). Even though finding conjugate
priors for two correlated binomial variables is challenging, the bivariate beta distribution
can be used as prior for correlated binomial random variables (Pham and Turkkan, 1992).
Even though it is not conjugate with correlated binomial variables, the computational
problem can be handled through Bayesian sampling methods.
A few bivariate beta distributions have been proposed in the statistical literature, differ-
ing mainly in the number of parameters and their attainable correlation ranges. Gupta
and Wong (1985) studied the five-parameter bivariate beta distribution, which is derived
from the Morgenstern-system of curves. However, the allowable correlations resulting
from this distribution are restricted (Schucany et al., 1978). Gupta and Wong also dis-
cussed a three-parameter bivariate beta distribution known as the Dirichlet distribution,
where the correlations here are restricted to negative values. Jones (2002) first provided
another three-parameter bivariate beta distribution through the links between beta and
F distributions. Olkin and Liu (2003) proposed an alternative way of generating the
exact formulation of this three-parameter bivariate beta distribution by using gamma
distributions.
Though in their original contexts, these models allow for five and three ”free” parameters
to be specified, their use as informative priors with ”known” marginal values reduces the
numbers of ”free” parameters. This has the unintended effect of reducing the range of
12
”allowable” correlation values. In this paper, we compare the attainable correlation range
of Morgenstern-type five-parameter bivariate beta distribution with three-parameter bi-
variate beta distribution introduced by Liu and Olkin under fixed marginal means.
2.2 3 and 5- parameter bivariate beta distribution
Suppose we have two correlated clinical outcomes, say X1 and X2. X1|b1 follows Bin(n1,
b1), where n1 is number of patients and b1 is the event rate in the study of X1 ; X2|b2
follows Bin(n2, b2), where n2 is number of patients and b2 is the event rate in the study
of X2 . Both distributions of X1 and X2 depend on distributions of b1 and b2, where
(b1, b2) jointly follow a bivariate beta distribution. Note that we could model b1 and b2
separately. Though we would then need a joint distribution for X1 and X2, the choice of
the distribution is not unique for fixed marginal distribution and association between X1
and X2. Therefore, instead of directly modeling the correlation between X1 and X2, the
correlation is modeled through the correlation between b1 and b2. We expect that two
clinical outcomes are positively correlated.
Suppose bj has marginal mean µj, where j = 1, 2. The degrees freedom (or free param-
eters) of the bivariate beta distribution is reduced from k to k − 2 by the imposition
of fixed marginal means, where k is number of parameters of a bivariate beta distri-
bution. Denote αj as shape parameter and βj as scale parameter for beta density of
random variable bj.The shape parameter is proportional to the scale parameter, such
that αj =
µj
1−µj βj = Cjβj, for j = 1, 2. The mean and variances of b1 and b2 can be also
easily obtained:
13
E(b1) = µ1 =
α1
α1 + β1
, V ar(b1) = σ
2
1 =
α1β1
(α1 + β1)2(α1 + β1 + 1)
E(b2) = µ2 =
α2
α2 + β2
, V ar(b2) = σ
2
2 =
α2β2
(α2 + β2)2(α2 + β2 + 1)
(2.1)
2.2.1 Correlation of three-parameter bivariate beta distribution
The density function for the three-parameter bivariate beta distribution proposed by
Olkin and Liu (2003) is given by
f(b1, b2) =
Γ(α1 + α2 + β)
Γ(α1)Γ(α2)Γ(β)
bα1−11 (1− b1)α2+β−1bα2−12 (1− b2)α1+β−1
(1− b1b2)α1+α2+β , (2.2)
where 0 < b1 < 1, 0 < b2 < 1. It can be shown that the marginal distributions of b1 and
b2 follow univariate beta distributions. Each marginal distribution shares a common scale
parameter β with each having different shape parameters (α1 for b1 and α2 for b2), thus
giving the bivariate beta distribution three degrees freedom. As is known, the univariate
beta distribution has a bell shape when both scale and shape parameters are greater than
1. The uniform distribution is achieved when both scale and shape parameters are equal
to 1. The univariate beta distribution with alpha and beta less than 1 has a u-shaped
curve which is not very useful for modeling in practice (Kelton and Law, 2000). Olkin
and Liu has shown that the shape of the joint density function also varies with different
combinations of (α1, α2, β). For large values of α1, α2 and β, the density is similar to a
bivariate normal density. For small values of α1, α2, β, the density is close to uniform.
Therefore, we will only focus on the region of α1 > 1, α2 > 1, β ≥ 1 , which provides a
bell shaped density for the prior information.
To calculate the correlation of the distribution, we utilize the following formula:
Corr(b1, b2) =
E(b1b2)− E(b1)E(b2)√
V ar(b1)V ar(b2)
(2.3)
14
The first moment E(b1b2) is integrated from the joint distribution of b1 and b2 :
E(b1b2) =
∫ 1
0
∫ 1
0
b1b2
Γ (α1 + α2 + β)
Γ (α1) Γ (α2) Γ (β)
bα1−11 (1− b1)α2+β−1bα2−12 (1− b2)α1+β−1
(1− b1b2)α1+α2+β db1db2
(2.4)
To simplify (2.4), the following results of integrals and formulas on the hypergeometric
function are applied (Abramowitz and Stegun (1964), Bailey (1935)):
2F1(a, b; c; z) = Γ(c)[Γ(b)Γ(c− b)]−1
∫ 1
0
tb−1(1− t)c−b−1(1− tz)−adt (2.5)
3F2(a, b, c; e, f ; z) =
Γ(e)Γ(f)Γ(s)
Γ(a)Γ(s+ b)Γ(s+ c)
3F2(e− a, f − a, s; s+ b, s+ c; z) (2.6)
where s = e+ f − a− b− c.
Therefore, E(b1b2) can be written as (see Appendix):
E(b1b2) =
α1α2
(α1 + β)(α2 + β)
∗3 F2(1, 1, β; β + α1 + 1, β + α2 + 1; 1) (2.7)
Substituting (2.3) with (2.7) and (2.1), the correlation between b1 and b2 in this 3-
parameter model then becomes:
Corr(b1, b2) =
√
α1α2(α1 + β + 1)(α2 + β + 1)
β2
{3F2(1, 1, β; β + α1 + 1, β + α2 + 1; 1)− 1}
=
√
α1α2
(α1 + β + 1)(α2 + β + 1)
∗
∞∑
j=1
j!Γ(β+j)
Γ(β+1)
Γ(α1+β+1+j)
Γ(α1+β+2)
Γ(α2+β+1+j)
Γ(α2+β+2)
(2.8)
With three degrees freedom, the correlation is free to range over [0,1]. In other words,
we can reach any correlation ranging from zero to one by choosing α1, α2 and β. Olkin
and Liu performed a simulation study to show how the correlation changes with different
choices of α1, α2 and β. They found that the correlation is large when the shape param-
eters (α1 and α2) are large and the scale parameter (β) is small, while, small values of
shape parameters (α1 and α2) and large value of scale parameters (β) yield small corre-
lation. However, the degree freedom is reduced to one when we specify a value for each
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of the marginal means (recall αj =
µj
1−µj β = Cjβ). Thus, the correlation only depends on
the value of β when the marginals are fixed:
Corr(b1, b2|β) =
√
C1C2β2
[(C1 + 1)β + 1][(C2 + 1)β + 1]︸ ︷︷ ︸
h(β)
∞∑
j=1
j!Γ(β+j)
Γ(β+1)
Γ[(C1+1)β+1+j]
Γ[(C1+1)β+2]
Γ[(C2+1)β+1+j]
Γ[(C2+1)β+2]︸ ︷︷ ︸
g(β)
(2.9)
We can see that the first part on the right of the correlation (2.9) is an increasing func-
tion of β, denoted as h(β). h(β) is then in the range
[√
C1C2
(C1+2)(C2+2)
,
√
C1C2
(C1+1)(C2+1)
)
given
β ≥ 1. Therefore, we have Corr(b1, b2|β) <
√
C1C2
(C1+1)(C2+1)
g(β) for any β ≥ 1.
The second part is also a function of β, denoted as g(β). The expansion of g(β) function
then becomes:
g(β) = 1 +
2(β + 1)
((C1 + 1)β + 2)((C2 + 1)β + 2)
+
2(β + 1)
((C1 + 1)β + 2)((C2 + 1)β + 2)
∗ 3(β + 2)
((C1 + 1)β + 3)((C2 + 1)β + 3)
+ · · · > 1
(2.10)
Each term in (2.10) is a decreasing function of β, therefore, g(β) is also a decreasing
function of β. Given β ≥ 1, the maximum value of g(β) is retained at β = 1. And as β
approximates infinity, g(β) approximates to 1. Therefore, g(β) is in the range (1, g(1)].
It can be easily shown that the inequality Corr(b1, b2|β) > h(β) holds for any β ≥ 1.
The correlation coefficient (2.9) is then bounded by the sequences h(β) and Kg(β):
h(β) < Corr(b1, b2|β) < Kg(β),where K =
√
C1C2
(C1 + 1)(C2 + 1)
and β ≥ 1 (2.11)
Clearly, we also have an approximate boundary for the correlation from (2.11):
min
β∈[1,∞)
h(β) < Corr(b1, b2|β) < K max
β∈[1,∞)
g(β) (2.12)
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2.2.2 Correlation of Morgenstern-type bivariate beta distribu-
tion
The joint density distribution of Farlie-Gumbel-Morgenstern (FGM) distributions has a
form of:
f(b1, b2) = [
2∏
j=1
f(bj)][1 + λ
2∏
j=1
{2F (bj)− 1}], b1, b2 > 1, |λ| ≤ 1 (2.13)
where f(bj) is the marginal density of bj, and F (bj) is the cumulative density function
(c.d.f) of bj. Integrating over the joint distribution,
E(b1b2) = E(b1)E(b2) + λ
∫ 1
0
b1{2F (b1)− 1}f(b1)db1
∫ 1
0
b2{2F (b2)− 1}f(b2)db2 (2.14)
Let g(b) =
∫ 1
0
b{2F (b) − 1}f(b)db. Using the Cauchy-Schwarz inequality, it has been
shown that g(b) ≤
√
1
3
σ by Schucany et al. (1978). Then, the general form of the
correlation is composed of the product of two univariate integrals, λ, and the marginal
variances as follows (see Appendix)
Corr(b1, b2) =
λg(b1)g(b2)
σ1σ2
≤ 1
3
λ (2.15)
Since λ is in the range of [-1,1], the correlation in the FGM distribution is bounded
between −1
3
and 1
3
for any specified marginal distributions. The corresponding FGM
bivariate beta distribution is obtained by having beta densities as the marginal distribu-
tions. The c.d.f of the beta distribution is given by
F (b) =
1
B(α, β)
∫ b
0
tα−1(1− t)β−1dt, α, β > 0 (2.16)
Note that (2.16) is the regularized incomplete beta function, and can be reformed in
terms of the gauss hypergeometric function
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F (b) =
1
B(α, β)
∫ b
0
tα−1
∞∑
k=0
Γ(1− β + k)tk
Γ(1− β)k! dt
=
bα
αB(α, β)
∞∑
k=0
(1− β)k(α)kbk
(α + 1)kk!
=
bα
αB(α, β)
2F1(α, 1− β;α + 1; b)
(2.17)
Through some calculations, we get
g(b) =
2
αB(α, β)2
∞∑
k=0
{
(1− β)k(α)k
(α + 1)kk!
∫ 1
0
b2α+k(1− b)β−1db
}
−
∫ 1
0
bf(b)db
=
2Γ(2α + 1)Γ(β)
αΓ(1 + 2α + β)B(α, β)2
∞∑
k=0
(1− β)k(α)k(1 + 2α)k
(α + 1)k(1 + 2α + β)kk!
− E(b)
= E(b){ 2B(1 + 2α, β)
αB(α, β)B(1 + α, β)
3F2(1− β, α, 1 + 2α; 1 + α, 1 + 2α + β; 1)− 1}
applying (2.6),
= E(b){ 2B(2α, 2β)
βB(α, β)B(α, β)
3F2(1, 1 + α + β, 2β; 1 + β, 1 + 2α + 2β; 1)− 1}
(2.18)
The correlation of b1 and b2 is
Corr(b1, b2) =
λE(b1)E(b2)
σ1σ2
2∏
j=1
{2B(2αj, 2βj)
βjB(αj, βj)2
∗ 3F2(1, 1 + αj + βj, 2βj; 1 + βj, 1 + 2αj + 2βj; 1)− 1}
(2.19)
Under specified marginal means,the correlation coefficient (2.19) is a product of λ and
a function of β1 and β2, denoted as g(β1, β2). The range of possible correlations are
determined by the range of g(β1, β2), since λ ∈ [−1, 1].
2.3 Calculation and comparison of correlation bounds
We selected different pairs of p1 and p2 to represent the proportions of success for two
treatment outcomes .To reflect the commonly experienced reality of small clinical differ-
ences between two proportions, we assumed the difference to be either 0.1 or 0.2. Table
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1 presents the boundary of the correlation for the three-parameter bivariate beta distri-
bution. We note that this boundary is not the attainable boundary for the correlation,
however, the boundary does provide some information on the performance of the distribu-
tion of the region, where β is as great as 1 and marginal means are fixed. The correlation
realized at any value of β will be constrained by the bounds presented in Table 2.1. The
correlation bounds depend on the value of p1 and p2. For small p1 and p2, the correlation
will also be small. For instance, the correlations are less than 0.3 and the bounds are
quite narrow, when p1 and p2 is out of any combination of (0.1, 0.2, 0.3). For large values
of p1 and p2 (0.5 to 0.8), the correlation is able to reach large values, but again its range
is restricted. The purpose of constructing these bounds is to show that the correlation
value of the three parameter bivariate beta distribution is not free on [0, 1]. Moreover,
the correlation is restricted to a narrow range given p1 and p2. In order to demonstrate
it, we plot the correlation against sequence h(β) (lower) and Kg(β) (upper) given β . As
presented in Figure 2.1, the maximum range between lower and upper corresponds to the
correlation boundary in Table 2.1. Figure 2.1a is the case of p1 = 0.1 and p2 = 0.2, and
the exact calculated correlation stays around 0.16. Figure 2.1b is the case of p1 = 0.6
and p2 = 0.8, and the exact calculated correlation ranges from 0.6 to 0.7. As β increases,
the range between the lower and upper boundaries asymptotically decrease to a point.
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Table 2.1: Approximate Correlation Boundary for Combinations of Efficacies
p1 p2 minh(β) maxKg(β)
0.1 0.2 0.0765 0.1646
0.1 0.3 0.0964 0.2016
0.2 0.3 0.1400 0.2852
0.2 0.4 0.1667 0.3293
0.3 0.4 0.2100 0.4033
0.3 0.5 0.2425 0.4509
0.4 0.5 0.2887 0.5206
0.4 0.6 0.3273 0.5703
0.5 0.6 0.3780 0.6376
0.5 0.7 0.4237 0.6887
0.6 0.7 0.4804 0.7544
0.6 0.8 0.5345 0.8065
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Figure 2.1: Correlation agianst the Bound given βs
(a) p1 = 0.1, p2 = 0.2 (b) p1 = 0.6, p2 = 0.8
(c) p1 = 0.3, p2 = 0.5 (d) p1 = 0.4, p2 = 0.5
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As we have discussed, the correlation of Morgenstern type bivariate distributions are
bounded between −1
3
and 1
3
in general. Figure 2.2 gives a contour plot of g(β1, β2) given
β1, β2 for the 5-parameter model. When we have specified beta marginals, we have
noticed that the correlation of the distribution is always positive for the cases we are
interested given 1 ≤ β1, β2 ≤ 20. For small p1 and p2 , the correlation varies from 0.2
to 0.3. As p1 and p2 increases, the size of the correlation decreases and the correlation
basically stays around 0.3 with minor variations. This property reduces the applicability
of the distribution on Bayesian modeling. Meanwhile, the large correlation values are not
allowed in the five parameter bivariate beta distribution, which is a serious disadvantage
on modeling correlated binomial data.
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Figure 2.2: Contour Plot for g(β1, β2) given (p1, p2)
(a) p1 = 0.1, p2 = 0.2 (b) p1 = 0.1, p2 = 0.3
(c) p1 = 0.2, p2 = 0.3 (d) p1 = 0.2, p2 = 0.4
(e) p1 = 0.3, p2 = 0.4 (f) p1 = 0.3, p2 = 0.5
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(g) p1 = 0.4, p2 = 0.5 (h) p1 = 0.4, p2 = 0.6
(i) p1 = 0.5, p2 = 0.6 (j) p1 = 0.5, p2 = 0.7
(k) p1 = 0.6, p2 = 0.7 (l) p1 = 0.6, p2 = 0.8
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2.4 Discussion
According to Table 2.1, we notice that the range of correlation is narrow for reasonable
values of marginal probabilities p1 and p2 for three parameter bivariate beta distribu-
tion. From this point, we are also interested in whether the five parameter bivariate beta
distribution (α1, β1, α2, β2, λ) proposed by Gupta and Wong is free on [-1,1] under the
same restriction for each of the marginal means. However, this five-parameter distribu-
tion is bounded from −1
3
to 1
3
. For lower values of p1 and p2, the five-parameter model
allows more possible correlation values than the three- parameter distribution in terms of
the maximum attainable correlation. However, the three-parameter allows larger corre-
lations when p1 and p2 get larger, while the five-parameter model does not. In practice,
we would appreciate the freedom to model the correlation as well as the marginal for
binomial correlated data. Therefore, neither of these models offer flexibility, and thus
seems unsuited for us as informative priors. It is possible that the copula functions may
offer wider possible correlations in the presence of fixed marginal priors. We will study
this possibility elsewhere.
2.5 Appendix
The Gaussian hypergeometric function 2F1(a, b; c; z) and the generalized hypergeometric
function 3F2(a, b, c; e, f ; z) are defined as:
2F1(a, b; c; z) =
∞∑
k=0
(a)k(b)k
(c)k
zk
k!
3F2(a, b, c; e, f ; z) =
∞∑
k=0
(a)k(b)k(c)k
(e)k(f)k
zk
k!
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where (a)k takes the form:
(a)k =
Γ(a+ k)
Γ(a)
= (a+ k − 1)(a+ k − 2)(a+ k − 3) · · · (a+ 2)(a+ 1)(a)
E(b1b2) =
∫ 1
0
∫ 1
0
b1 ∗ b2 Γ (α1 + α2 + β)
Γ (α1) Γ (α2) Γ (β)
bα1−11 (1− b1)α2+β−1bα2−12 (1− b2)α1+β−1
(1− p1p2)α1+α2+β db1db2
=
Γ (α1 + α2 + β)
Γ (α1) Γ (α2) Γ (β)
∫ 1
0
∫ 1
0
bα11 (1− b1)α2+β−1bα22 (1− b2)α1+β−1
(1− p1p2)α1+α2+β db1db2
=
Γ (α1 + α2 + β)
Γ (α1) Γ (α2) Γ (β)
∫ 1
0
∫ 1
0
∞∑
j=0
Γ(α1 + α2 + β + j) ∗ bα1+j1 (1− b1)α2+β−1
Γ(α1 + α2 + β)j!
∗ bα2+j2 (1− b2)α1+β−1db1db2
=
Γ (α1 + α2 + β)
Γ (α1) Γ (α2) Γ (β)
∞∑
j=0
Γ(α1 + α2 + β + j)
Γ(α1 + α2 + β)
Γ(α1 + 1 + j)Γ(α2 + β)
Γ(α1 + α2 + β + 1 + j)
∗ 1
j!
∗ Γ(α2 + 1 + j)Γ(α1 + β)
Γ(α1 + α2 + β + 1 + j)
=
Γ(α1 + α2 + β)Γ(α2 + β)Γ(α1 + β)
Γ(β)Γ(α1 + α2 + β + 1)Γ(α1 + α2 + β + 1)
∞∑
j=0
(α1 + α2 + β)n(α1 + 1)n
(α1 + α2 + β + 1)n
∗ (α2 + 1)n
(α1 + α2 + β + 1)n
1
j!
=
α2α1
α1 + α2 + β
Γ(α2 + β)Γ(α1 + β)
Γ(β)Γ(α1 + α2 + β + 1)
∗
3F2(α1 + α2 + β, α1 + 1, α2 + 1;α1 + α2 + β + 1, α1 + α2 + β + 1; 1)
Define v = α1 + α2 + β,
E(b1b2) =
α2α1
v
Γ(α2 + β)Γ(α1 + β)
Γ(β)Γ(v + 1)
∗ Γ(v + 1)Γ(v + 1)Γ(β)
Γ(v)Γ(α1 + β + 1)Γ(α2 + β + 1)
∗3 F2(1, 1, β; β + α1 + 1, β + α2 + 1; 1)
=
α1α2
(α1 + β)(α2 + β)
∗3 F2(1, 1, β; β + α1 + 1, β + α2 + 1; 1)
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The Cauchy-Schwarz inequality is stated as | ∫ f(x)g(x)dx |2≤ ∫ f(x)2dx ∫ g(x)2dx.
g(b) =
∫ 1
0
b{2F (b)− 1}f(b)db
=
∫ 1
0
(b− E(b)){2F (b)− 1}f(b)db , where
∫ 1
0
{2F (b)− 1}f(b)db = 0
≤
√∫ 1
0
(b− E(b))2f(b)db
∫ 1
0
(2F (b)− 1)f(b)db
≤
√
1
3
σ
Chapter 3
Bivariate Response Adaptive Design
Part I (written as manuscript)
3.1 Background
Optimal response adaptive randomization designs are intended to minimize the risk of
patients being assigned to an inferior treatment, given treatment outcomes (i.e. survival,
remission) of previous patients. The average power of the procedure is a decreasing func-
tion of the variability of the randomization (Hu and Rosenberger, 2003). This leads to
the trade-off between power and expected number of failures. The procedure is required
to be the fully sequential, which means data need to be immediately observed, to balance
the trade-off.
In practice, the primary clinical outcome may take a long term to be observed, especially
in cancer trials (i.e. survival, remission). Therefore, there is usually a delay in the al-
location rate update for the next patient or group of patients. However, the efficiency
of the response adaptive design highly depends on the immediacy of observed data. If
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few primary endpoints are observed at the early stage, little information is available to
make the decision for the modification of the trial, which undermines the advantage of
the design. A paper by Bai et al. (2002) has shown that moderate delay in response
will not affect the asymptotic property of the adaptive procedure under certain delay
mechanisms, however, the allocation rate through the trial is directly affected and there
is a higher risk of assigning more patients to the inferior treatment.
3.2 Rationale
In the classical response adaptive procedure, the aim is to minimize the loss function given
that the information level at each stage is constant, which has the form that contains
the treatment efficacy difference (θ = pA − pB, where pA and pB are the success rates for
treatment A and B) and sample size (ni = nA,i + nB,i ) (Jennison and Turnbull):
L(θ) = u(θ)nA,i + v(θ)nB,i , subject to
σ2A
nA,i
+
σ2B
nB,i
= K (3.1)
where nA,i and nB,i refer to cumulative number patients assigned to treatment A and
treatment B at ith stage, u(θ) is the loss for a patient allocated to treatment A, and v(θ)
is the loss for a patient allocated to treatment B.
In randomization, patients are actually exposed to two risks: treatment failure and as-
signed to inferior treatment. Let θ < 0 indicate treatment A is inferior (pA < pB) and
θ > 0 indicate treatment B is inferior (pA > pB). The treatment failure risk are described
by u(θ) and v(θ), which are functions that depend on the value of θ. The function u(θ)
increases as θ decreases and v(θ) increases as θ increases. The allocation ratio (nA,i/nB,i)
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determines the probability of assigning patient to the inferior treatment. The loss function
then integrates the two risks to which patients are exposed and our goal is to minimize
this loss function subject to the constant variability at each stage. Assume σ2A and σ
2
B
are the known variances of the population responses to treatment A and treatment B,
respectively. The minimization of equation (3.1) can be solved for the allocation ratio
using delta method (see Appendix), and the minimized allocation ratio is:
R =
nA,i
nB,i
=
σA
σB
√
v(θ)
u(θ)
(3.2)
For Binary response trials, if u(θ) = v(θ) = 1, the allocation ratio R = σA
σB
=
√
pAqA
pBqB
is
Neyman allocation (Melfi and Page, 1998). Neyman allocation minimizes the total sample
size given fixed variance. If u(θ) = 1−pA and v(θ) = 1−pB, the allocation ratio R =
√
pA
pB
turns out to be RSIHR allocation (also called Optimal allocation), which minimizes the
expected number of treatment failures (Rosenberger et al., 2001). Consequently, we need
only to model u(θ) and v(θ) to realize a specific objective. u(θ) and v(θ) can also be
treated as functions of unknown parameter pA and pB, which can be estimated based on
patient responses using sequential estimation method. Since each adaptation depends on
the previous estimates of u(θ) and v(θ), the accuracy of the estimates effects the whole
adapative procedure. With delayed primary response, we have little information to make
an accurate adaptation decision for the incoming patients.
In this paper, we are motivated to incorporate an auxiliary outcome that is easily ob-
served and highly positively correlated with the primary outcome in the response adaptive
randomization procedure. Such a procedure will need to take into account information
from both the auxiliary and primary outcomes. Especially during early stages of random-
ization, we usually do not have enough information to update allocation ratio. A long
lag time to observe primary outcome weakens the advantage of the response adaptive
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design. Auxiliary outcomes provide additional information about the primary outcome
and revive the adaptation procedure with delayed primary response. Then, the problem
is how to appropriately incorporate the auxiliary outcome into the adaptation process
along with the primary outcome. Bibby and Væth (2011) proposed a two-dimensional
beta binomial distribution to fit the model for calculating the correlation of two count
data. The distribution illuminates an approach to construct the bivariate variable model
for the adaptive design. Based on the classical response adaptive design framework, we
propose a new response adaptive design for binary data using both the auxiliary outcomes
and primary outcomes. The goals of this paper are: 1) to introduce a response adaptive
design framework that simultaneously use both primary and auxiliary outcomes, and 2)
to utilize a bivariate beta distribution (Olkin and Liu, 2003) as prior distribution for
correlated binomial data, to account for dependence between the two outcomes.
3.3 Method
3.3.1 New design using auxiliary and primary outcomes
For treatments j= A or B, suppose Xj is an auxiliary outcome for treatment j, Yj is a
primary outcome for treatment j, where Xj and Yj both are binary variables. According
to the observed outcome sequence, we denote P1,j as the auxiliary efficacy and P2,j as the
primary efficacy for treatment j.
We make the following assumptions about the design that 1) P1,j, P2,j are random vari-
ables and the joint distribution of P1,j, P2,j follows a bivariate beta distribution, 2) The
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conditional random variables Xj|P1,j ∼ Bin(n1,j, P1,j) and Yj|P2,j ∼ Bin(n2,j, P2,j) are
independent, where n1,j and n2,j are the sample size of auxiliary and primary outcomes,
and 3) the correlation between Xj and Yj is explained through the correlation of P1,j and
P2,j.
The posterior distribution of P1 and P2 can be expressed as:
f(P1, P2|X, Y ) ∝ f(X|P1)f(Y |P2)f(P1, P2) (3.3)
As we have mentioned earlier, u(θ) and v(θ) are positive weight that measures the risk of
assigning patients to treatment A and B given primary efficacies (P2,A, P2,B). In addition,
we also have auxiliary efficacies P1,A and P1,B, which offer the information about P2,A
and P2,B respectively. Therefore, it is reasonable to average the u(θ) and v(θ) over all
possible set of P2,A and P2,B given (P1, X, Y )A and (P1, X, Y )B. Based on loss function
(3.1) of the classical adaptive design framework, the loss function of the procedure using
auxiliary and primary outcomes takes the following form:
L(θ) = E[u(θ)|(P1, X, Y )A, (P1, X, Y )B)]nA,i + E[v(θ)|(P1, X, Y )A, (P1, X, Y )B)]nB,i
(3.4)
where nA,i and nB,i are the number of patients in treatment A and B at i
th stage. The
two conditional expectations in (3.4) can be calculated through the conditional posterior
distribution from (3.3).
The classical response adaptive design adopts equal increments of information at each
stage, which means we update the allocation ratio after each subject or group of subjects
are enrolled. Following in this trend, we will have
σ2YA
nA,i
+
σ2YB
nB,i
= K, where σ2YA and σ
2
YB
are variances of primary outcomes and assumed to be known. The minimization of the
function (3.4) is the same as that of the loss function (3.1) in classical response adaptive
design framework, since the conditional expectations are assumed to be known. There-
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fore, the allocation ratio is R∗ =
σYA
σYB
√
E[v(θ)|(P1,X,Y )A,(P1,X,Y )B ]
E[u(θ)|(P1,X,Y )A,(P1,X,Y )B ] .
3.3.2 Two-dimensional beta-binomial model
Olkin and Liu (2003) generated a bivariate beta distribution from three gamma dis-
tributed random variables, in order to provide a prior for correlated binomial distribu-
tions. As we discussed in Chapter 2, the bivariate beta distribution has limitations on
the correlation of two variables. However, we still want to see the performance of the
distribution serving as prior for (P1,j, P2,j). Given the assumptions about the design, the
joint distribution of (Xj, Yj, P1,j, P2.j) is the product of condition distributions of Xj|P1,j
and Yj|P2.j, and prior distribution of (P1,j, P2,j).
To simplify our notation, the following distributions are generalized to any (X, Y, P1, P2)
given a specific treatment.
f(X, Y, P1, P2) = f(X, Y |P1, P2) ∗ f(P1, P2;α1, α2, β)
=
(
n1
x
)
px1(1− p1)n1−x
(
n2
y
)
py2(1− p2)n2−y
∗ Γ (α1 + α2 + β)
Γ (α1) Γ (α2) Γ (β)
pα1−11 (1− p1)α2+β−1pα2−12 (1− p2)α1+β−1
(1− p1p2)α1+α2+β
(3.5)
Integrating with respect to P2, the joint distribution of X, Y, P1 is:
f(X, Y, P1) =
(
n1
x
)(
n2
y
)
Γ (α1 + α2 + β)
Γ(α1)Γ(α2)Γ(β)
px+α1−11 (1− p1)α2+β−1+n1−x
∗ Γ (y + α2) Γ (α1 + β + n2 − y)
Γ (α1 + α2 + β + n2)
∗2 F1(α1 + α2 + β, y + α2;
α1 + α2 + β + n2; p1)
(3.6)
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where 2F1 is the Gaussian hypergeometric function. Therefore, the conditional distribu-
tion of P2 given P1 and the data X, Y is easily obtained:
f(P2|X, Y, P1) = f(X, Y, P1, P2)/f(X, Y, P1)
=
Γ (α1 + α2 + β + n2)
p
y+α2−1
2 (1−p2)α1+β−1+n2−y
(1−p1p2)α1+α2+β
Γ (y + α2) Γ (α1 + β + n2 − y)
∗ 1
2F1(α1 + α2 + β, y + α2;α1 + α2 + β + n2; p1)
(3.7)
As presented in the defined loss function, u(θ) and v(θ) are function of P2,A and P2,B.
Also, we know that treatment A is independent from treatment B, which indicates
f(X, Y, P1, P2)A and f(X, Y, P1, P2)B are independent. As long as we know the con-
ditional distribution f(P2|X, Y, P1)A and f(P2|X, Y, P1)B for treatment A and B, we are
able to calculate the conditional expectation from the loss function (3.4).
In this paper, we only focus on the case when u(θ) = 1 − P2,A and v(θ) = 1 − P2,B, re-
calling that P2,j is the primary efficacy rate in the j
th treatment. Then, the loss function
form is reduced to
L(θ) = (1− E[P2,A|(P1, X, Y )A])nA,i + (1− E[P2,B|(P1, X, Y )B])nB,i (3.8)
The optimal allocation ratio can be rewritten as R∗ =
σ2YA
σ2YB
√
E[1−P2,B |(P1,X,Y )B ]
E[1−P2,A|(P1,X,Y )A] .
For a given treatment, the conditional expectation is a function of X, Y, P1 with prior
parameters (β, α1, α2) (see Appendix).
E[P2|P1, X, Y ] = y + α2
α1 + α2 + β + n2
∗2F1(α1 + α2 + β, y + α2 + 1;α1 + α2 + β + n2 + 1; p1)
2F1(α1 + α2 + β, y + α2;α1 + α2 + β + n2; p1)
(3.9)
We may notice that the expression on the right side of the equation is the gauss con-
tinued function. The continued function of Gaussian hypergeometric function converges
uniformly for 0 < p1 < 1. Therefore, E[P2|P1, X, Y ] is guaranteed to reside within the
range (0,1). And the correlation of X and Y is proportional to the correlation of P1 and
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P2 and takes the form (see Appendix):
corr(X, Y ) =
√
n1n2
(α1 + β + n1)(α2 + β + n2)
corr(P1, P2) (3.10)
3.3.3 Prior density choice
In the binomial-beta model, subject matter expertise can be used to provide some in-
formation to assess the probability of having a success event, which then determines the
mean or mode of the beta distribution. The total (r) of α and β determines the variance
of the beta distribution given the marginal. The larger the total r, the more compact
will be the prior distribution. Basically, this r indicates how confident we are on the
expert advice or literature information, and r− 2 is known as effective sample size. If we
lack confidence on the prior belief of success probability, we will weight the data more by
taking a wide unimodal beta density function (i.e. by selecting low r). For the bivariate
beta distribution case, we still adopt the same logic to select marginal density, which
follows the beta distribution. Recalling that the prior correlation of Olkin and Liu’s
distribution is bounded in a narrow range when the marginal means are given, the inflex-
ibility of modeling correlation diminishes the reliability of the bivariate prior distribution.
According to (3.10), the correlation of auxiliary and primary outcomes approximate to
the correlation of auxiliary and primary efficacy as (n1, n2) >> (α1, α2, β). Therefore, we
intend to have a less informative prior by choosing r no greater than 15 when α1, α2 and
β are greater than 1. As studied in Olkin and Liu’s paper, the bivariate beta distribution
tends to have a bivariate normal density when α1, α2 and β are large.
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3.3.4 Estimation rule for allocation rate
Although the allocation rate depends on the unknown parameters, we will apply the
sequential sampling rule following the trend of optimal adaptive design to update the al-
location rate. The prior parameters (β, α1, α2) reveal the knowledge about the correlation
between the auxiliary and primary outcomes (X and Y ) and efficacies of the outcomes
(P1 and P2) for a specific treatment. Based on clinician experience or pilot study, we
are able to determine an appropriate combination of (β, α1, α2) that satisfy
α1
α1+β
≈ prior
P1 and
α2
α2+β
≈ prior P2. Let paired (xk, yk) be the auxiliary and primary outcome for
kth subject. Let Tk be the treatment indicator for k
th subject. As mentioned earlier, the
primary outcome might not be available immediately to update the allocation ratio for
the next coming patient, though the auxiliary outcome should be selected so that it will
be quickly available before the next accrued patient.
Let Iyk indicate whether the primary response for the k
th patient become accessible when
a new patient is enrolled in the study. Let F ((x1, y1), (x2, y2), . . . , (xk, yk), . . . , (xi−2, yi−2), (xi−1,
yi−1); Iy1 , Iy2 , . . . , Iyk , Iyi−2 , Iyi−1 ;T1, T2, T3, · · · , Ti−2, Ti−1
)
be the history of the first i− 1
patients, denoted as F (•)i−1. Based on F (•)i−1, we have following results for the ith
stage:
n1,A,i =
i−1∑
k=1
Tk, n1,B,i =
i−1∑
k=1
(1− Tk)
xA,i =
i−1∑
k=1
xkTk, xB,i =
i−1∑
k=1
xk(1− Tk)
n2,A,i =
i−1∑
k=1
IykTk, n2,B,i =
i−1∑
k=1
Iyk(1− Tk)
yA,i =
i−1∑
k=1
ykIykTk, yB,i =
i−1∑
k=1
ykIyk(1− Tk)
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3.3.5 Algorithm of the design
The algorithm for conducting the proposed adaptive design is:
(1) Set initial allocation rate to be 0.5 for the first patient.
(2) Update auxiliary efficacy for treatment A and B with estimates p˜1,A =
α1,A+xA,i−1
α1,A+βA+nA,i−1
and p˜1,B =
α1,B+xB,i−1
α1,B+βB+nB,i−1
for the ith stage.
Even though the auxiliary outcome is obtainable immediately, it is always the case that
the empirical estimate (sample proportion) of P1 is either overestimated or underesti-
mated due to its sensitivity on extremes values. The empirical estimate performs better
as the sample size gets larger. Instead of using sample proportions, posterior means of
auxiliary outcomes are an appropriate choice for the estimation of auxiliary efficacy. As
it is known, posterior means are weighted averages of the sample proportion and prior
mean. Notice that the posterior distribution of the auxiliary outcome is given by the
beta-binomial distribution.
(3). Calculate R∗ by substituting E(P2,A | p˜1,A, F (•)i−1), E(P2,B | p˜1,B, F (•)i−1), σˆ2Y,A,
and σˆ2Y,B.
Sample variances would be a good choice for σˆ2Y,A, and σˆ
2
Y,B given enough data, for the
reason that they are maximum likelihood estimator of variances. Also, they are easy
to compute and save computational time in the procedure. However, primary outcomes
are binary data and their variances are associated with their means. We might not be
able to calculate the sample variance for treatments at early stages, which could re-
sult from response-delay, no event observed, or patients clustered in one treatment. For
i ≤ k, the estimated variance for treatment j adopts the posterior conditional variance
V ar(P2,j | p˜1,j, F (•)i−1), for i > k, the empirical sample variance yj,i−1(nj,i−1−yj,i−1)n2j,i−1 is sub-
stituted, where j=treatment A or B, and k is the stage where sample variance is available
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for both treatment groups.
(4). Repeat (2) and (3).
(5). Terminate the randomization depending on the specified stopping rule (eg. final
sample size, primary end-point or toxicity).
3.4 Simulation
3.4.1 Simulation targets
In the simulation study, we are interested in modeling different clinical scenarios to see
the performance of our bivariate model allocation method compared with RSIHR allo-
cation and balanced allocation: 1) how different primary outcomes between treatment
A and B affect simulation results, in terms of allocation proportions, number of patients
assigned to each treatment, error rate, number of treatment failures, 2) how different of
auxiliary efficacies affect the simulation results, and 3) how a delay in primary response
affect the simulation results.
3.4.2 Sampling method
We plan to compare our proposed method with RSIHR allocation and balanced alloca-
tion methods. Let us consider each simulation as a single trial. Intuitively, simulations of
each method are done separately with large amount of trials. However, to model random
events in this way may not approximate the real clinical trial setting, since the trial is
actually an observed sequence of random variables. Then, it will be more realistic to
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generate NA random observations from treatment A population and NB random obser-
vations from treatment B population for each single trial. Each method works on the
same pool of subjects. Suppose N is the total sample size of the clinical trial, then NA
and NB should both be greater than N . Within a trial, three allocation methods will
actually share the same sample pool that simulate from populations of treatment A and
B. Across trials, the sample pool is regenerated for each trial. Therefore, we are able to
reduce variation between trials. The variation between the trials caused by sample pools
randomly generating from the populations of treatment A and B.
The sample size of balanced allocation is fixed in advanced, while the sample size of the
adaptive methods is allowed to adjust during the trial. In order to make allocation proce-
dures comparable, the total sample size is selected to yield 0.90 power of two-sided t-test
for balanced allocation in each case. Correlated binomial responses are sampled from
a multinomial distribution given both auxiliary and primary efficacies with a specified
correlation. Notice that this correlation is not free range to [−1, 1], due to the joint prob-
ability of auxiliary and primary outcomes being calculated to obey the Frechet bounds.
We assume that the correlation between auxiliary and primary outcomes is fixed regard-
less of treatment effect. In other words, the auxiliary outcome contains certain amount
of information about primary outcome, no matter which treatment a patient receives.
3.4.3 Simulation settings
1) Lead-in sample
RSIHR allocation utilizes the primary outcome to update allocation ratio. The allocation
ratio is calculated based on the sample proportion and sample variance. As we mentioned
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earlier, these sample estimates are not estimable at the early stage of the trial, when no
variability exits in treatment responses or no response is available by the time the next
patient enrolled in the study. A lead-in is introduced to the simulation process, which
means that patients in the lead-in phase are assigned to treatments with equal probabil-
ity.
2) Prior parameter selection
Prior distributions take into account the uncertainty of P1 and P2 before observed data
is considered. Recalling that auxiliary and primary efficacies (P1 and P2) follow beta
distributions, α1 and β are the shape and scale parameters for prior distribution on aux-
iliary efficacy (P1), and α2 and β are shape and scale parameters for prior distribution on
primary efficacy (P2). In the simulation study, we already know the true efficacies (p1, p2)
of treatment A and treatment B, though in practice, we do not know(p1, p2). Therefore,
the mean of prior distributions are set to some values around p1 and p2, which gives us
the equations of α1
α1+β
≈ priorP1 and α2α2+β ≈ priorP2. Given these two equations, the
relationship among (α1, α2, β) is determined. As long as we know the correlation between
P1 and P2, the combination of (α1, α2, β) can be resolved. The expectation of P1 and
P2 varies for different treatment but the correlation between P1 and P2 stays the same
regardless of treatments.
3) Cases
Our method is to target the scenario that the primary outcome has a rare event rate and
the auxiliary outcome has a moderate event rate. Such as, the primary efficacy ranges
from 0.1 to 0.3, and auxiliary efficacy ranges from 0.4 to 0.7. Due to the limitation of
the correlation of bivariate beta distribution on this model, the correlation has a narrow
window (see Chapter 2). We assume the correlation between auxiliary and primary out-
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comes are 0.5 for all cases. Recall that our bivariate optimal method aims to alleviate
the restriction of classic response design on response delay. In the following cases, we
assume a scenario that 30 patients have delay in primary outcome in the trial, to reflect
the realistic scenario that observation of the primary outcome is delayed. Alternatively,
we assure that the auxiliary outcome is immediately observed.
3.4.4 Results
To make explanation easier, we refer to our proposed method as bivariate optimal method
and RSIHR allocation method as the univariate optimal method. Table 3.1 presents the
number of patients assigned to treatment B (the more effective treatment) given the sam-
ple size. When treatment B is better than treatment A (0.1 vs 0.2 or 0.1 vs 0.3), the
bivariate optimal method assigns more patients to the beneficial treatment than dose the
univariate optimal method. Also, the bivariate optimal method is more sensitive to treat-
ment differences. Roughly, 64% (104/162) of patients are allocated to treatment B when
there is 0.2 clinical difference, and 59.5% (313/526) patients are allocated to treatment
B when the clinical difference is reduced to 0.1. However, the univariate optimal method
results in 58% (304/526 or 95/162) of patients allocated to treatment B when the clinical
difference is either 0.1 or 0.2. Both bivariate and univariate optimal methods intend
to equally assign patients to treatments when no clinical difference presents. It seems
that the bivariate optimal method depends slightly on the auxiliary efficacies, which only
changes decimal places of the number of patients assigned to superior treatment. The
effect of clinical difference overwhelms the effect of auxiliary efficacy difference and dom-
inates the direction of allocation. For no clinical difference case (0.3 vs 0.3), the auxiliary
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outcome difference protracts the allocation to be balanced. For instance, 97 out of 200
patients are assigned to treatment B while the univariate optimal and balance methods
assigns 100 patients to the treatment.
The advantage of response adaptive designs is that they reduce treatment failures, as
compared to traditional randomization designs. Therefore, Table 3.2 shows the expected
number of patient failures using the three methods, corresponding to the cases presented
in Table 3.1. If a clinical difference displays, the bivariate and univariate optimal method
perform substantially better than the balance method in terms of reducing patient fail-
ures. Compared with the univariate optimal method, the results of bivariate optimal
method are not statistically enhanced, though there is a small improvement in all cases
considered. Generally, Balance method has slightly smaller standard deviation than the
other two optimal methods, and the variability of the two adaptive methods are similar.
Within paired primary outcomes, the number of patient failures slightly varies across
different combination of auxiliary efficacies, which does not appear to substantially affect
the number of patient failures.
Table 3.3 gives the power/error rates of the two sided chi-square test at the observed
end of trial. The type I error of rejecting the null hypothesis is near nomial 0.05 level
when there is no clinical difference for each method. The bivariate and univariate optimal
methods perform well. Their power is as good as that achieved using balanced random-
ization. Our proposed bivariate optimal method decreases the number of patient deaths
and preserves the power.
We are also interested in comparing the bivariate with the univariate optimal method
with respect to allocation rate. In order to simplify the comparison, we present the me-
dian with interquartile range (IQR) after 25%, 50%, and 75% of patients have accrued.
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For instance, the total sample size for the case 0.1 vs 0.2 is 526, then the 25 percentile of
the visits is 132 ( 0.25*256). Table 3.4 shows the allocation rates assigned to treatment
A with IQR at the 25th percentile visit. The allocation rates are similar at the 25th
percentile visit. However, when the clinical difference increases to 0.2 ( 0.1 vs 0.3 ), the
allocation rate is distinguishable between the two methods at the early stage. Due to
a delay in the primary response, the univariate optimal method adopts the ”preset” 0.5
allocation ratio. The median probability of assigning a patient to treatment A is 0.33-
0.34 with a narrow IQR. When there is no clinical difference (0.3 vs 0.3), the allocation
rate varies around 0.5. The bivariate optimal method has slightly narrower IQR than the
univariate optimal method. As patients were accrued, table 3.5 displays the allocation
rate at the 50th percentile visit. For the case 0.1 vs 0.3, we notice that the bivariate
optimal method intends to put more patients on the beneficial treatment (trt B) than
does the univariate optimal method. For the other two cases, the allocation rates are
similar. The main reason is that we have more information on primary responses and
weight less on auxiliary responses, as the adaptation proceeds longer ( at large number
of the visit). The results of using the bivariate method confirms with that of using the
univariate optimal method at the end of the adaptation process, regardless of clinical
difference and auxiliary outcome differences. Table 3.6 demonstrates the steadiness of
the two methods at the end of adaptation process.
3.5 Discussion
Using auxiliary outcomes to facilitate classic response adaptive design is promising at
early stages of a trial, particularly when primary outcomes are delayed. Unlike the uni-
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variate optimal method (classic response design), the bivariate optimal method provides
more information with which to allocate patients to beneficial treatment at the beginning
of randomization. The bivariate optimal method results in fewer expected number of fail-
ures, while retains comparable power level as the univariate optimal method and balance
allocation method. There is a substantial clinical reduction in treatment failures from
balanced method to both univariate and bivariate optimal methods. Also, it seems that
the level of auxiliary outcome does not directly impact the allocation ratio and direction
during the adaptation process. This might be caused by the limitation of the correlation
of bivariate beta distribution, which serves as prior for the correlated binary outcomes.
To solve this problem, we will consider avoiding this restriction by using Copula methods
in further study.
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Table 3.1: Summary Number of Patients in Group B (receiving more effective
treatment)
Primary Auxilary Sample
Size
Method
trtA trtB trtA trtB Bivariate [1] Univariate [2] Balance [3]
0.1 0.3
0.4 0.7
162
104.0 95.4 80.9
0.4 0.6 104.7 96.0 81.1
0.5 0.7 104.0 95.5 81.1
0.5 0.6 104.8 95.2 80.8
0.6 0.6 104.9 95.4 81.6
0.1 0.2
0.4 0.7
526
313.4 304.8 263.5
0.4 0.6 312.2 304.4 262.8
0.5 0.7 312.1 305.0 263.0
0.5 0.6 313.6 305.4 263.2
0.6 0.6 313.0 305.0 263.1
0.3 0.3
0.4 0.6
200
99.7 99.9 100.3
0.6 0.5 100.8 100.1 99.8
0.5 0.5 100.0 100.3 99.8
0.7 0.5 97.1 99.9 100.0
[1] New proposed bivariate adaptive design.
[2] Optimal adaptive design.
[3] Balanced randomization design.
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Table 3.2: Summary of Expected Number of Patient Failures (SD)
Primary Auxilary Method
trtA trtB trtA trtB Bivariate Univariate Balance
0.1 0.3
0.4 0.7 125.0 (5.64) 126.7 (5.58) 129.9 (4.98)
0.4 0.6 124.6 (5.54) 126.4 (5.55) 129.5 (5.13)
0.5 0.7 125.1 (5.41) 126.8 (5.42) 129.5 (4.99)
0.5 0.6 124.8 (5.38) 126.7 (5.34) 129.5 (5.20)
0.6 0.6 124.8 (5.45) 126.6 (5.38) 129.7 (5.16)
0.1 0.2
0.4 0.7 442.4 (8.59) 443.2 (8.48) 447.3 (7.94)
0.4 0.6 442.1 (8.61) 443.0 (8.49) 447.1 (8.23)
0.5 0.7 441.8 (8.48) 442.5 (8.40) 447.5 (8.12)
0.5 0.6 441.8 (8.89) 442.5 (8.77) 447.3 (8.11)
0.6 0.6 442.2 (8.60) 443.1 (8.66) 447.4 (8.33)
0.3 0.3
0.4 0.6 140.0 (6.84) 140.1 (6.76) 140.2 (6.79)
0.6 0.5 140.0 (6.43) 140.0 (6.41) 140.0 (6.37)
0.5 0.5 139.8 (6.39) 139.9 (6.30) 139.9 (6.32)
0.7 0.5 139.9 (6.46) 139.9 (6.50) 139.9 (6.38)
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Table 3.3: Summary of Power/Error Rate
Primary Auxiliary Method
trtA trtB trtA trtB Bivariate Univariate Balance
0.1 0.3
0.4 0.7 0.91 0.91 0.91
0.4 0.6 0.91 0.92 0.91
0.5 0.7 0.90 0.90 0.91
0.5 0.6 0.92 0.92 0.91
0.6 0.6 0.91 0.91 0.91
0.1 0.2
0.4 0.7 0.92 0.91 0.91
0.4 0.6 0.90 0.92 0.89
0.5 0.7 0.90 0.89 0.92
0.5 0.6 0.91 0.91 0.90
0.6 0.6 0.90 0.90 0.88
0.3 0.3
0.4 0.6 0.06 0.06 0.06
0.6 0.5 0.05 0.05 0.05
0.5 0.5 0.05 0.05 0.04
0.7 0.5 0.04 0.04 0.05
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Table 3.4: Summary of Allocation Rate (IQR) at the 25th Percentile Visit for Trt A
Primary Auxiliary Method
trtA trtB trtA trtB Bivariate Univariate
0.1 0.3
0.4 0.7 0.34 (0.32, 0.37) 0.50 (0.50, 0.50)
0.4 0.6 0.33 (0.32, 0.36) 0.50 (0.50, 0.50)
0.5 0.7 0.33 (0.32, 0.37) 0.50 (0.50, 0.50)
0.5 0.6 0.33 (0.31, 0.36) 0.50 (0.50, 0.50)
0.6 0.6 0.33 (0.31, 0.35) 0.50 (0.50, 0.50)
0.1 0.2
0.4 0.7 0.41 (0.36, 0.45) 0.41 (0.37, 0.45)
0.4 0.6 0.41 (0.36, 0.46) 0.41 (0.36, 0.46)
0.5 0.7 0.41 (0.36, 0.46) 0.41 (0.37, 0.46)
0.5 0.6 0.41 (0.37, 0.45) 0.41 (0.37, 0.45)
0.6 0.6 0.41 (0.36, 0.45) 0.41 (0.37, 0.45)
0.3 0.3
0.4 0.6 0.50 (0.46, 0.54) 0.50 (0.45, 0.55)
0.6 0.5 0.50 (0.46, 0.54) 0.50 (0.45, 0.55)
0.5 0.5 0.50 (0.47, 0.53) 0.50 (0.45, 0.55)
0.7 0.5 0.51 (0.46, 0.55) 0.50 (0.45, 0.55)
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Table 3.5: Summary of Allocation Rate (IQR) at the 50th Percentile Visit for Trt A
Primary Auxiliary Method
trtA trtB trtA trtB Bivariate Univariate
0.1 0.3
0.4 0.7 0.35 (0.32, 0.41) 0.38 (0.32, 0.44)
0.4 0.6 0.35 (0.32, 0.41) 0.37 (0.32, 0.43)
0.5 0.7 0.36 (0.32, 0.41) 0.38 (0.32, 0.43)
0.5 0.6 0.36 (0.32, 0.41) 0.38 (0.32, 0.44)
0.6 0.6 0.36 (0.32, 0.41) 0.38 (0.32, 0.43)
0.1 0.2
0.4 0.7 0.41 (0.38, 0.44) 0.41 (0.38, 0.44)
0.4 0.6 0.41 (0.38, 0.44) 0.41 (0.38, 0.44)
0.5 0.7 0.41 (0.38, 0.44) 0.41 (0.38, 0.44)
0.5 0.6 0.41 (0.38, 0.44) 0.42 (0.38, 0.44)
0.6 0.6 0.41 (0.38, 0.44) 0.41 (0.38, 0.44)
0.3 0.3
0.4 0.6 0.50 (0.47, 0.53) 0.50 (0.47, 0.53)
0.6 0.5 0.50 (0.47, 0.53) 0.50 (0.47, 0.53)
0.5 0.5 0.50 (0.47, 0.53) 0.50 (0.47, 0.53)
0.7 0.5 0.50 (0.47, 0.53) 0.50 (0.47, 0.53)
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Table 3.6: Summary of Allocation Rate (IQR) at the 75th Percentile Visit for Trt A
Primary Auxiliary Method
trtA trtB trtA trtB Bivariate Univariate
0.1 0.3
0.4 0.7 0.36 (0.32, 0.40) 0.36 (0.31, 0.40)
0.4 0.6 0.36 (0.32, 0.40) 0.36 (0.31, 0.40)
0.5 0.7 0.36 (0.32, 0.40) 0.36 (0.32, 0.40)
0.5 0.6 0.36 (0.31, 0.40) 0.36 (0.32, 0.40)
0.6 0.6 0.36 (0.31, 0.40) 0.36 (0.32, 0.41)
0.1 0.2
0.4 0.7 0.41 (0.39, 0.43) 0.41 (0.39, 0.43)
0.4 0.6 0.41 (0.39, 0.43) 0.41 (0.39, 0.43)
0.5 0.7 0.41 (0.39, 0.43) 0.41 (0.39, 0.43)
0.5 0.6 0.42 (0.39, 0.44) 0.42 (0.39, 0.44)
0.6 0.6 0.41 (0.39, 0.44) 0.41 (0.39, 0.44)
0.3 0.3
0.4 0.6 0.50 (0.48, 0.52) 0.50 (0.48, 0.53)
0.6 0.5 0.50 (0.48, 0.52) 0.50 (0.47, 0.52)
0.5 0.5 0.50 (0.48, 0.52) 0.50 (0.48, 0.52)
0.7 0.5 0.50 (0.48, 0.53) 0.50 (0.48, 0.53)
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3.6 Appendix
3.6.1 Response adaptive allocation
min[u(θ)nA,i + v(θ)nB,i] subject to
σ2A
nA,i
+
σ2B
nB,i
= C (3.11)
Define allocation ratio Ri =
nA,i
nB,i
, and ni = nA,i+nB,i is the total sample size at i
th stage.
Using langrange multiplier method to find the local miminal of the function (3.11), subject
to the constraint. The optimization problem (3.11) can be reformed as:
Minimize h(Ri, ni) = u(θ)
Ri
1+Ri
ni + v(θ)
1
1+Ri
ni, subject to g(Ri, ni) =
σ2A(1+Ri)
Rini
+
σ2B(1+Ri)
Rini
We take derivatives of the function Λ(Ri, ni, λ) = h(Ri, ni) + λ
(
g(Ri, ni)−C
)
respect to
Ri, ni, λ and set derivatives to zero.
∂Λ(Ri, ni, λ)
∂Ri
= 0,
∂Λ(Ri, ni, λ)
∂ni
= 0,
∂Λ(Ri, ni, λ)
∂λ
= 0 (3.12)
Then, we have
u(θ)ni
(1 +Ri)2
− v(θ)ni
(1 +Ri)2
+ λ
[
σ2B
ni
− σ
2
A
niR2i
]
= 0 (3.13)
u(θ)Ri
1 +Ri
+
v(θ)
1 +Ri
− λ
[
σ2A(1 +Ri)
Rini
+
σ2B(1 +Ri)
n2i
]
= 0 (3.14)
σ2A(1 +Ri)
Rini
+
σ2B(1 +Ri)
Rini
= 0 (3.15)
Through (3.14) and (3.15), we have
ni =
(
1 +Ri
)(
σ2A +Riσ
2
B
)
CRi
, λ =
(
σ2A +Riσ
2
B
)(
u(θ)Ri + v(θ)
)
C2Ri
Substitute ni and λ into (3.13), we have(
u(θ)− v(θ))(σ2A +Riσ2B)
(1 +Ri)CRi
+
(
u(θ)Ri + v(θ)
)
(σ2BR
2
i − σ2A)
(1 +Ri)C2R2i
= 0
⇒ (u(θ)− v(θ))(σ2A +Riσ2B)Ri + (u(θ)Ri + v(θ))(σ2BR2i − σ2A) = 0
⇒ (Ri + 1)(σ2Bu(θ)R2i − σ2Av(θ) = 0
⇒ Ri = σA
σB
√
v(θ)
u(θ)
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3.6.2 Conditonal expectation
Using Euler’s formula
F (a, b; c; z) = Γ(c)[Γ(b)Γ(c− b)]−1 ∗
∫ 1
0
tb−1 ∗ (1− t)c−b−1(1− tz)−adt
we can easily calculate E[P2|P1, X, Y ].
E[P2|P1, X, Y ] =
∫ 1
0
p
y+α2
2 (1−p2)α1+β−1+n2−y
(1−p1p2)α1+α2+β dp2
Γ(y+α2)Γ(α1+β+n2−y)
Γ(α1+α2+β+n2)
∗2 F1(α1 + α2 + β, y + α2;α1 + α2 + β + n2; p1)
=
Γ(y+α2+1)Γ(α1+β+n2−y)
Γ(α1+α2+β+n2+1)
∗2 F1(α1 + α2 + β, y + α2 + 1;α1 + α2 + β + n2 + 1; p1)
Γ(y+α2)Γ(α1+β+n2−y)
Γ(α1+α2+β+n2)
∗2 F1(α1 + α2 + β, y + α2;α1 + α2 + β + n2; p1)
=
y + α2
α1 + α2 + β + n2
∗ 2F1(α1 + α2 + β, y + α2 + 1;α1 + α2 + β + n2 + 1; p1)
2F1(α1 + α2 + β, y + α2;α1 + α2 + β + n2; p1)
3.6.3 Correlation between X and Y
E[X|P1] = n1P1, E[Y |P2] = n2P2
E[XY ] = E[E[XY |P1, p2] = E[E[X|P1]E[Y |P2]] = n1n2E[P1P2]
V ar(X) = V ar(E(X|P1]) + E(V ar(X|P1)] = n21V ar(P1) + n1
(
E(p1)− E[p21]
)
= n21V ar(P1)− n1(α1 + β + 1)var(P1) = n1(α1 + β + n1)V ar(P1)
V ar(Y ) = n2(α2 + β + n2)V ar(P2), corr(X, Y ) =
√
n1n2
(α1+β+n1)(α2+β+n2)
corr(P1, P2)
Therefore, the correlation of X and Y is linear function of the correlation of P1 and P2.
Chapter 4
Bivariate Response Adaptive Design
Part II (written as manuscript)
4.1 Introduction
Randomized controlled trials (RCTs) are standard tools used to evaluate the effectiveness
of interventions (treatments) on particular outcomes (e.g. death or survival rate). They
help to ensure that patients are not consciously or unconsciously enrolled to receive treat-
ments in a preferential manner. Therefore, RCTs help minimize selection and allocation
bias (Schulz and Grimes, 2002). Response adaptive randomization has become popular
in recent years in the study of Phase III trials, and utilizes accumulated outcomes from
enrolled patients to assign an allocation ratio for the next patient or group of patients
(Hu and Rosenberger, 2006).
For the purpose of ethicality, patients are favored to the beneficial treatment in the pro-
cess of optimal allocation. However, outcome adaptive designs depend on the availability
of outcomes. When the primary end point is a rare event or takes a long time to be
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observed, adaptive designs do not offer much benefit. In order to solve this problem, we
attempt to implement an ancillary outcome, which contains some information about the
primary outcome, to the design. By means of joint modeling of the primary and ancillary
outcomes, the allocation ratio is based on the inferences from the posterior distribution
of primary efficacy conditional on the observed auxiliary efficacy.
In Chapter 3, we used a three-parameter bivariate beta distribution proposed by Olkin
and Liu (2003) as prior distribution to describe the association of primary and auxiliary
efficacies and then construct the model to estimate the allocation ratio for the adaptation.
For a certain treatment with specified marginals, the three parameters of the bivariate
distribution are reduced to 1 degree freedom. We have showed the limitation of the
bivariate beta distribution, which imposes a small correlation range when the marginal
means are fixed (see Chapter 2). This inflexibility stimulates us to find a bivariate prior
distribution to reach a wider range of correlation given fixed marginal distributions.
Copula theory provides an approach to generate joint distributions in cases where a for-
mal or intuitive joint distribution does not exist or is algebraically intractable. This
theory also frees the constraints on association parameters due to their separate mod-
eling from the fixed marginal distributions. The copula function can be viewed as a
dependence function and links the multivariate distribution to several one-dimensional
marginal distributions. Regardless of the form of the marginal distributions, we can
modify the copula function to describe the dependence of the random variables. Due to
its flexibility, the copula theory has been popularly applied to study quantitative risk
management methodology within finance and insurance fields (Jaworski, 2010). Shih and
Louis (1995) modeled the association of bivariate failure times (survival data) through
copula functions, and Burzykowski et al. (2001) proposed two different copula models for
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validating surrogate end points in multiple RCTs when the primary end point is treat-
ment failure.
In this Chapter, we apply copula-based joint distribution to realize the adaptation of
our proposed bivariate response adaptive design. Simulation studies are conducted to
compare the results of the design using bivariate binomial-beta model (Chapter 3), in
terms of number of patients assigned to treatments, expected number of patient failures,
power/error rate, and allocation ratio at 25th, 50th, and 75th percentile of enrollment.
4.2 Response adaptive design
The response adaptive design allows the allocation ratio (R) to be sequentially adapted
based on the accumulated observed outcomes to hopefully assign patients to a ”better”
treatment, without violating the validation and integrity of the trial. Several adaptive
procedures have been introduced in the clinical trial literature, such as randomized play
the winner rule (Wei and Durham, 1978), optimal response adaptation (Rosenberger
et al., 2001), and drop-the-loser (Ivanova, 2003). The response adaptive design focuses
on the trade-off between the power (sample size) and number of patients receiving infe-
rior treatment. In this paper, we develop a new response adaptive design based on the
optimal response design. The optimal response adaptive design attains certain optimiza-
tion criteria (e.g. number of patient failures, power) given that the information of each
adaptation stage (the variance of efficacy end points) is constant.
Suppose two treatments (A and B) are studied, where nA,i is accumulated number of
patients in treatment A and nB,i is accumulated number of patients in treatment B at
ith stage. The optimal problem for two treatments can be considered as (Jennison and
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Turnbull):
R = arg min
R
{u(θ)nA,i + v(θ)nB,i} , subject to η(θ, nA, nB) = C (4.1)
where u(θ) and v(θ) are the positive weights on the treatment groups. θ represents the
efficacy end points, and there are three commonly used end points: treatment difference
(pA − pB), relative risk
(
pA
pB
)
, and odds ratio
(
pA(1−pB)
pB(1−PA)
)
. η(θ, nA, nB) is the function
of sample size and efficacy end point, which usually refers to the information known at
each stage and retained equally. The consistency of the procedure information protects
the power of the design, since the power of the analysis is a decreasing function of the
procedure variability. In Chapter 3, we have discussed how the optimal allocation ratio
can be solved using Lagrange multipliers when the treatment difference is the efficacy
end point. The allocation ratio takes the form:
Ri =
nA,i
nB,i
=
σA
σB
√
v(θ)
u(θ)
(4.2)
From equation 4.2, we notice that the optimization problem actually depends on how we
establish u(θ) and v(θ) in the design assuming variances are known. For instance, they
can be units to minimize the average sample size (Neyman allocation). Or, they can be
weighted as failure rates to minimize the expected number of patients (so-called RSIHR
or optimal allocation).
The efficacy end point associates with unknown parameter pA and pB, the primary effi-
cacies, which are estimated with the observed primary outcomes. However, it is common
for primary outcomes to not be available for up to weeks, months or years for any given
subject. It is also common for the event to be rare, such as survival studies for cancer
patients.
We incorporate the concept of auxiliary outcomes to u(θ) and v(θ) for both treatments.
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An auxiliary outcome is not viewed as an replacement of the primary outcome, but as
a positively associated companion of the primary outcome, which can be almost imme-
diately collected from patients. Suppose the auxiliary outcome is collected at stage 1,
and primary outcome becomes available at stage 2. Let p1 be auxiliary outcome efficacy
and p2 be primary outcome efficacy. For the randomization with two treatments, the
auxiliary outcome assists the primary outcome in assigning patients in the following way:
Ri =
nA,i
nB,i
=
σA
σB
√
v (θ(p2,A, p2,B)|p1,A, p1,B,X,Y)
u (θ(p2,A, p2,B)|p1,A, p1,B,X,Y)
(4.3)
where θ(p2,A, p2,B) is a function of primary outcome efficacies p2,A, p2,B, denoted as θ(·).
We assumed that (p1, p2) are joint distributed and follow a certain distribution. There-
fore, we take the expectation of v (θ(·)|p1,A, p1,B,X,Y) and u (θ(·)|p1,A, p1,B,X,Y) to
average all possible values over the range of p2,A, p2,B. In this paper, we are interested
in minimizing the expected number of patients failures when E[u (θ|p1,A, p1,B,X,Y))] =
E[p2,A|p1,A, XA, YA] and E[v (θ|p1,A, p1,B,X,Y)] = E[p2,B|p1,B, XB, YB]. The allocation
ratio is then updated as:
Ri =
nA,i
nB,i
=
σA
σB
√
E[p2,B|p1,B, XB, YB]
E[p2,A|p1,A, XA, YA] (4.4)
4.3 Method
Suppose X|P1 and Y |P2 are independent, and the joint distribution of X, Y, P1 and P2
is :
f(X, Y, P1, P2) = f(X|P1)f(Y |P2)f(P1, P2)
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4.3.1 Prior distribution
Copula theory
The joint cumulative distribution function (c.d.f) of P1 and P2 is defined as F (p1, p2) =
Pr(P1 ≤ p1, P2 ≤ p2), and the marginal c.d.fs of P1 and P2 are defined as u = F (x)
and v=F (y). Then, u and v are uniformly distributed. The quantile functions of the
marginals are p1 = F
−1(u) and p2 = F−1(v) (with one to one mapping). Then the joint
c.d.f of X and Y can be reformed as:
F (p1, p2) =Pr(P1 ≤ p1, P2 ≤ p2)
=Pr(P1 ≤ F−1(u), P2 ≤ F−1(v))
=Pr(F (P2) ≤ u, F (P2) ≤ v)
=Pr(U ≤ u, V ≤ v)
=C(u, v)
(4.5)
According to Sklar’s theorem, C(u,v) is a uniquely defined copula function if the joint
distribution is specified with marginals F (x) and F (y). Conversely, if F (P1), F (P2) and
C(u, v) are distribution functions, then F (x, y) is a unique joint distribution of P1 and
P2 (Sklar, 1973). The joint density function takes the form:
f(p1, p2) =
∂2
∂p1∂p2
C(u, v)
=
∂u
∂p1
∂v
∂p2
∂2
∂u∂v
C(u, v)
=f(p1)f(p2)c(u, v)
(4.6)
If C(u, v) is the c.d.f, then c(u, v) is the corresponding density function. From equation
4.6, we notice that the dependence between P1 and P2 is solely described by the function
c(u, v), which is independent from the marginals. This independence gives us the flexi-
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bility to create a joint distribution by separately modeling the copula function and the
marginal distributions.
The joint distribution F (p1, p2) is naturally bounded by the Fre`chet-Hoeffing bounds
(Fre´chet, 1951 and Hoeffding). The lower and upper bounds (for two variables) are
defined as:
FLower(p1, p2) = max [F (p1) + F (p2)− 1, 0] ,
FUpper(p1, p2) = min [F (p1), F (p2)]
(4.7)
FLower(p1, p2) and FUpper(p1, p2) are also copulas. Therefore, the graph of the copula
C(u,v) is a continuous surface in between the graph of Fre`chet-Hoeffing bounds within
the unit cubic space. The bounds are corresponding to negative and positive dependence
for the bivariate cases. In other words, the copula is equivalent to the upper bound when
each of P1 and P2 is an almost surely increasing function of the other. The copula is
equivalent to the lower bound when each of P1 and P2 is an almost surely decreasing
function of the other.
Copula function
It is important to select an appropriate copula function for the data, because it describes
the dependence structure between variables. The copula function can be categorized
into two types: elliptical copulas and Archimedean copulas. The elliptical copulas are
generated from the distribution that has elliptical contour. The Archimedean copulas
are generated from a specified generator function (Nelsen, 2006), and they have simple
forms and are able to capture wide ranges of dependence. For our purpose of study, we
choose the Gaussian (Lee, 1983) and Clayton copula, the representatives of the two major
copulas, to study the performance of the bivariate optimal design.
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Gaussian Copula The Gaussian copula achieves the maximum lower and upper Frechet
bounds. Also, a multivariate distribution based on a Gaussian copula is similar to the
multivariate normal distribution (Xue-Kun Song, 2000). These properties are promising
for the practical application on modeling dependence between random variables. The
bivariate Gaussian copula takes the form:
CG(u, v; ρ) = ΦG(Φ(u)
−1,Φ(v)−1; ρ) (4.8)
where Φ(·) is the c.d.f of standard normal distribution, and ΦG(u, v; ρ) is the c.d.f of
standard bivariate normal distribution with correlation ρ.
Clayton Copula The Clayton (1978) copula is one type of the so-called Archimedean
copula (Kimberling, 1974). And the following form in the bivariate case:
CClayton(u, v; γ) = (u
−γ + v−γ − 1)−1/γ (4.9)
where γ indicates the level of dependence between u and v. The density function of the
clayton copula is derived as:
c(u, v) =
∂2
∂u∂v
Cclyaton(u, v; γ)
=(γ + 1)(u−γ + v−γ − 1)− 1γ−2u−γ−1v−γ−1
(4.10)
The Kendall’s tao correlation for this copula is γ
γ+2
. In contrast to the Gaussian cop-
ula, the Clayton copula presents an asymmetric property on the dependence, where the
asymptotic left tail dependence is λL = 2
−1/γ, and the asymptotic right tail dependence
is close to zero (Fusai and Roncoroni, 2008), meaning it exhibits stronger dependence
on left tail than on the right. Due to this property, the Clayton copula is suitable for
the scenario when two outcomes exibit low event rates and high positive dependence. In
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our scenario, we focus on low primary efficacy (0.1 to 0.3) and slightly higher auxiliary
efficacy (0.4 to 0.6), both with strong positive dependence. Therefore, the Clayton copula
is a good choice of comparison with Gaussian copula.
Marginal distribution
After choosing the copula function, we pick the marginal distribution based on our knowl-
edge about the data. Since the parameter of interest is the probability of event occurrence,
the beta distribution suits for the case and appropriately describes our initial beliefs about
the auxiliary and primary efficacy (P1 and P2).
4.3.2 Metropolis-Hastings algorithm
The Metropolis-Hastings (MH) algorithm has been extensively used to generate a se-
quence of random samples from same target distribution, especially when the prior dis-
tribution and the likelihood function are not conjugated or where the full conditional
posterior distribution is not in closed form. Unlike the Gibbs sampling method, the MH
algorithm requires a function only be proportional to the target distribution. In our sce-
nario, we are interested in sampling from pi(P2|P1,X,Y ), where P2 is primary efficacy,
P1 is auxiliary efficacy, and (X,Y ) are auxiliary and primary outcomes.
Selecting starting values p01, p
0
2 from uniform(0,1), the MH algorithm proceeds as follow
(for t in [1,T] ):
1) Draw p∗1 and p
∗
2 from proposed transition kernel q1(·|pt−11 ) amd q2(·|pt−12 ).
2) Compute MH accept-reject ratio:
α(p∗1, p
t−1
1 ) = min
(
pi(p∗1, p
t−1
2 ,X,Y )q1(p
t−1
1 |p∗1)
pi(pt−11 , p
t−1
2 ,X,Y )q1(p
∗
1|pt−11 )
, 1
)
(4.11)
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α(p∗2, p
t−1
2 ) = min
(
pi(p∗2, p
t−1
1 ,X,Y )q2(p
t−1
2 |p∗2)
pi(pt−12 , p
t−1
1 ,X,Y )q2(p
∗
2|pt−12 )
, 1
)
(4.12)
3) Accept p∗1 with probability α(p
∗
1, p
t−1
1 ) and p
∗
2 with probability α(p
∗
2, p
t−1
2 ), otherwise,
pt1 and p
t
2 remain at the previous stage p
t−1
1 and p
t−1
2 .
4) Repeat (1), (2), (3) until the Markov chain has length of T.
4.3.3 Convergence diagnostic
The MH algorithm is based on the theory of Monte Carlo Markov Chains (MCMC),
and we expect that the chain converges to the same stationary distribution (our target
distribution) after a large number of iterations, regardless of the starting points selected
for each parameter (i.e. P1 and P2). The simulation draws after t iterations are used as
a sample from the stationary distribution. When the starting points are not in the high
density region of the target distribution, the chain might converge slowly toward the target
distribution. Therefore, it is important to have multiple starting points and diagnose
the convergence of the Markov chains. Rubin and Gelman (1992) have constructed an
approach to detect the convergence of the stochastic process using multiple sequences.
Suppose we have M number of chains, and ”burn in” (ie. remove) the first k draws. The
Gelman and Rubin’s diagnostics for each parameter are:
1) Calculate the average of the M within-chain variability, W =
∑m
j=1 s
2
j/m, where s
2
j =∑n
i=1(τij − τ¯.j)2)/(n− 1) is the variance of jth chain, τ¯.j is the sample mean for jth chain.
n is number of draws in each chain (exluding the burn-in draws).
2) Calculate between-chain variability, B =
∑m
j=1 (τ¯.j − τ¯..)2 /(m − 1), where τ¯.. is the
overall sample mean for M chains.
3) The estimate of the target variance can be expressed as weighted average of within-
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chain and between-chain variances, V ar(τ) = n−1
n
W +B
4) The potential scale reduction ratio is the ratio of the estimated variance to within-
variance, Ω =
√
V ar(τ)df
W (df−2) . (Note that if df →∞ as n→∞, then dfdf−2 → 1.) If the Markov
chains converge to the target distribution, then the between-chain variance is diminished
and the ratio is near 1. Otherwise, the ratio is greater than 1 and the Markov chains
need more time to converge.
4.3.4 Simulation algorithm
Suppose the sample size that attained 90% power under balanced randomization is N,
and the delayed primary outcome is D. Denote x and y as the auxiliary and primary
outcomes.
The algorithm proceeds as follows:
1) Allocate patient i based on Ri; if i=1, Ri set to be 0.5.
2) Update Ri+1 based on accumulated data from the 1st to the i
th patient. For treatment
j, where j=A or B :
a. Obtain candidate p∗1,j and p
∗
2,j from kernel distributions q(p
∗
1,j, p
c
1,j) and q(p
∗
2,j, p
c
2,j).
• pc1,j and pc2,j are the current values of p1,j and p2,j.
• kernel distributions q(·) for both p1,j and p2,j are chosen to be beta distributions;
their location parameters α’s are determined by pc1,j and p
c
2,j with specified scale
βs. Scale βs are chosen to yield moderate variance. For simple reason, we fix βs to
be 15.
b. Compute the densities pi
(
p∗2,j, p
c
1,j,xj ,yj
)
, pi
(
p∗1,j, p
c
2,j,xj ,yj
)
, and pi
(
pc2,j, p
c
1,j,xj ,yj
)
.
• xij , yij are the corresponding vectors that contain auxiliary and primary outcomes
63
accumulated until the ith stage in the jth treatment group.
• pi(p1, p2,xi,yi) =
∏ni
i=1 f(xi, yi|p1, p2) ∗ f(p1)f(p2)c(p1, p2)
c. Reject/accept p∗1,j and p
∗
2,j with probability α1 and α2.
• α1 = pi(p
∗
1,j |pc2,j ,xj ,yj)
pi(pc1,j |pc2,j ,xj ,yj)
q(pc1,j |p∗1,j)
q(p∗1,j |pc1,j) =
pi(p∗1,j ,pc2,j ,xj ,yj)
pi(pc1,j ,pc2,j ,xj ,yj)
q(pc1,j |p∗1,j)
q(p∗1,j |pc1,j)
• α2 = pi(p
c
1,j ,p
∗
2,j ,xj ,yj)
pi(pc1,j ,pc2,j ,xj ,yj)
q(pc2,j |p∗2,j)
q(p∗2,j |pc2,j)
d. Repeat a, b, and c until convergence
e. Calculate E(p2,j|p1,j, Xj, Yj) by averaging overall MCMC sample of p2,j for M chains
and V ar(p2|p1, X, Y ) by averaging the mean square error for overall MCMC sample of
p2,j or using sample variance.
3) Repeat (1) and (2) until i=N.
4.4 Result
In order to make results comparable with bivariate optimal design using bivariate beta
distribution (see Chapter 3), we focus on the cases when primary efficacies are 0.1 vs 0.2,
0.1 vs 0.3 , and 0.3 vs 0.3 and auxiliary efficacies are 0.4 vs 0.6, 0.5 vs 0.6 with varying
in associations, and there is a 30 patients lag between primary response and enrollment.
4.4.1 Gaussian copula simulation results
Recalling Chapter 3, we have used sample variances whenever it is available for the
adaptation because it decreases the number of expected patient failures. In this copula
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optimal design, we want to compare the performance of the adaptations when the esti-
mates variances for both treatments are posterior variances and sample variances. Table
4.1 presents the number of patients allocated to the better treatment (trt B). It shows
that cases using the sample variance assign more patients to better treatment than cases
using the posterior variances. The difference in auxiliary efficacies does not affect the
treatment assignments when the Pearson correlation of the copula is fixed (ρ = 0.5 or 0.8
). When the difference of primary efficacies is smaller than that of auxiliary efficacies,
it seems that moderate correlation (ρ = 0.5 ) case assigns more patients in treatment B
than higher correlation (ρ = 0.8). It might be the impact of sample variances on assign-
ment cancels out the correlation effect, so this trend is apparently showed in the scenario
of posterior variance used.
Table 4.2 shows the expected number of patient failures. The Copula optimal method
using the sample variance has a smaller number of expected patient failures at the cost of
slightly larger standard deviation, compared with the method using posterior variance.
Given paired primary efficacies, the numbers of patient failures are similar regardless of
auxiliary efficacy difference and correlation for each method.
Table 4.3 depicts the power/error rate of the studies, which is estimated as the number of
correct rejecting the null hypothesis out of all simulations. Error rate shows the chance of
incorrectly rejecting the null hypothesis when there is no difference between treatments.
Each case attains the level of 90% power no matter which estimated variances are uti-
lized in the adaptation. It seems that the correlation associates with error rate level when
auxiliary efficacy difference does not reflect the direction of treatment difference. When
there is no treatment difference, the case with high correlation (ρ = 0.8 ) has slightly
higher odds of making the wrong conclusion.
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We are also interested in how the allocation rate adapts across the trials. Table 4.4
displays the allocation rate of treatment A at the 25th percentile of visits (early stage).
When treatment difference exists, the allocation rate starts to favor the better treatment
(trt B) and assign less patient to treatment A. Otherwise, the allocation rate stays in
balance (around 0.5). Compared with early stages, the allocation rate at the 50th per-
centile visit (middle stage) gradually moves towards a smaller rate with a narrower IQR
(see Table 4.5). When the study approaches the 75th percentile visit, the allocation rate
nearly remains at same rate as in middle stage of the trial (see Table 4.6).
4.4.2 Clayton copula simulation results
We have noticed that the design performs better using sample variance than using poste-
rior variance in terms of expected number of patient failures. Therefore, the simulation
for Clayton copula-based model will adopt sample variances to compare with the results
of Gaussian copula-based model (i.e. we will not study the posterior variance). Table
4.7 presents the number of patients assigned to the better treatment group (group B).
Compared with Gaussian copula-based model, the Clayton copula-based model assign
less patients to group B by about 2 patients for the case when primary efficacy difference
is small (0.1) or there is no difference. Regarding to expected number of patient failures
(see Table 4.9), no difference exists between Gaussian and Clayton copula-based models.
Table 4.8 shows the power/error rate of the studies using the Clayton copula-based model.
When a treatment difference exists, the power remains around 90% as was observed in
the Gaussian copula-based model. However, the type I error rates are smaller value using
the Clayton copula-based model for the case when primary and auxiliary end points are
highly correlated.
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Table 4.10, 4.11, 4.12 summarize the shift of allocation rate of assigning patients to
treatment A at the 25th, 50th, and75th percentiles of enrollment. At early stage of the
enrollment, the allocation rates of assigning patient to treatment A for the cases (0.1 vs
0.2 and 0.3 vs 0.3) are slightly higher than that of Gaussian copula model. As the adap-
tion continues, the allocation rates of Clayton copula-based model are similar to that of
Guassian copula-based model.
4.5 Discussion
Unlike the bivariate binomial-beta model, copula-based bivariate response adaptive design
gives us the flexibility to model the dependence between auxiliary and primary endpoints.
We have compared the simulation results of applying Gaussian and Clayton copula in
the model. We noticed that the Clayton copula-based model is slightly more conserva-
tive than Gaussian copula-based in terms of assigning patients to the better treatment
when there is a small treatment difference. The Clayton copula-based model is better
in preserving type I error for high dependent outcomes than the Gaussian copula based-
model. We know that it is easy to control the power of the study by having sufficient
sample size. However, the major challenge for an adaptive design is to control the inflated
overall type I error when a shift of allocation rate exists (Feng et al., 2007). Due to the
inherent unbalance allocation, the power of the study decreases. Therefore, the choice
of the copula is critical to the study. As the primary efficacies are small, the number of
expected patient failures would not be asymptotically different using either copula-based
model or the bivariate binomial-beta model. The allocation rates depend on the unknown
variance of the population. One thing we did notice is that variance estimates strongly
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affect the allocation rates and indirectly change the expected number of patient failures.
The adaptation performs better using empirical sample variances than using posterior
variances. The problem with using sample variance is that it might not available at the
early stage or with delayed responses. Hence, we suggest using the posterior variance at
the early stage when sample variance is not estimable. Once the sample variance becomes
available, we will apply sample variance instead of posterior variance.
Table 4.1: Summary Number of Patients in Group B (Gaussian Copula)
Primary Auxiliary Sample
Size
Posterior variance [1] Sample variance [2]
trtA trtB trtA trtB ρ=0.5 ρ=0.8 ρ=0.5 ρ=0.8
0.1 0.3
0.40 0.60
162
89.50 90.00 99.00 98.30
0.50 0.60 89.90 90.20 98.90 98.70
0.1 0.2
0.40 0.60
526
285.40 283.40 310.40 309.20
0.50 0.60 285.70 283.80 309.60 308.20
0.3 0.3
0.40 0.60
200
99.70 97.80 100.30 99.30
0.50 0.60 100.00 98.30 100.50 100.10
[1] using posterior variance to update the allocation rate.
[2] using sample variance to update the allocation rate.
ρ indicates the pearson correlation of the Gaussian copula function.
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Table 4.2: Summary of Expected Number of Patient Failures (SD) (Gaussian Copula)
Primary Auxiliary Posterior variance Sample variance
trtA trtB trtA trtB ρ=0.5 ρ=0.8 ρ=0.5 ρ=0.8
0.1 0.3
0.40 0.60 127.7 (5.21) 127.7 (5.17) 125.9 ( 5.44 ) 126.4 ( 5.48 )
0.50 0.60 127.8 (5.18) 127.6 (5.20) 125.9 (5.30) 126.0 (5.33)
0.1 0.2
0.40 0.60 445.3 (8.28) 445.1 (8.03) 442.0 (8.47) 442.0 (8.77)
0.50 0.60 444.8 (8.46) 445.1 (8.07) 442.1 (8.41) 442.2 (8.41)
0.3 0.3
0.40 0.60 139.8 (6.42) 139.8 (6.73) 139.9 (6.42) 140.3 (6.35)
0.50 0.60 140.0 (6.42) 139.9 (6.23) 140.1 (6.53) 140.0 (6.45)
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Table 4.3: Summary of Power/Error Rate (Gaussian Copula)
Primary Auxiliary Posterior variance Sample variance
trtA trtB trtA trtB ρ=0.5 ρ=0.8 ρ=0.5 ρ=0.8
0.1 0.3
0.40 0.60 0.92 0.92 0.90 0.90
0.50 0.60 0.92 0.90 0.92 0.92
0.1 0.2
0.40 0.60 0.90 0.91 0.91 0.90
0.50 0.60 0.90 0.91 0.91 0.90
0.3 0.3
0.40 0.60 0.06* 0.06* 0.05* 0.07*
0.50 0.60 0.04* 0.06* 0.05* 0.06*
Note: ∗ indicates error rates.
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Table 4.7: Summary Number of Patients in Group B (Clayton Copula)
Sample
Size
Primary Auxiliary Sample variance
trtA trtB trtA trtB γ=2 γ=8
162 0.1 0.3
0.40 0.60 99.00 98.70
0.50 0.60 99.30 99.30
526 0.1 0.2
0.40 0.60 307.40 304.4
0.50 0.60 308.40 – –[1]
200 0.3 0.3
0.40 0.60 98.80 98.00
0.50 0.60 99.00 98.60
[1] Based on results of the cases where γ = 8, I terminate the simulation of this
case.
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Table 4.8: Summary of Power/Error rate (Clayton Copula)
Primary Auxiliary Sample Variance
trtA trtB trtA trtB γ=2 γ=8
0.1 0.3
0.40 0.60 0.92 0.91
0.50 0.60 0.91 0.91
0.1 0.2
0.40 0.60 0.91 0.91
0.50 0.60 0.90 – –
0.3 0.3
0.40 0.60 0.06 0.06
0.50 0.60 0.05 0.04
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Table 4.9: Summary of Expected Number of Patient Failures (SD) (Clayton Copula)
Primary Auxiliary Sample Variance
trtA trtB trtA trtB γ=2 γ=8
0.1 0.3
0.40 0.60 126.1 (5.64) 126.3 (5.38)
0.50 0.60 126.1 (5.65) 126.1 (5.66)
0.1 0.2
0.40 0.60 442.6 (8.92) 443.3 (8.59)
0.50 0.60 442.3 (8.3) – –
0.3 0.3
0.40 0.60 140.3 (6.64) 139.8 (6.46)
0.50 0.60 139.8 (6.49) 140.2 (6.28)
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Table 4.10: Summary of Allocation Rate (IQR) at the 25th Percentile Visit for Trt A
(Clayton Copula)
Primary Auxiliary Sample Variance
trtA trtB trtA trtB γ=2 γ=8
0.1 0.3
0.40 0.60 0.41 (0.33, 0.48) 0.4 (0.32, 0.48)
0.50 0.60 0.39 (0.32, 0.48) 0.38 (0.32, 0.47)
0.1 0.2
0.40 0.60 0.44 (0.36, 0.51) 0.44 (0.35, 0.52)
0.50 0.60 0.43 (0.35, 0.50) – –
0.3 0.3
0.40 0.60 0.5 (0.43, 0.57) 0.5 (0.44, 0.56)
0.50 0.60 0.51 (0.45, 0.57) 0.51 (0.44, 0.57)
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Table 4.11: Summary of Allocation Rate (IQR) at the
50th Percentile Visit for Trt A (Clayton Copula)
Primary Auxiliary Sample Variance
trtA trtB trtA trtB γ=2 γ=8
0.1 0.3
0.40 0.60 0.37 (0.30, 0.42) 0.38 (0.31, 0.42)
0.50 0.60 0.37 (0.31, 0.42) 0.37 (0.30, 0.42)
0.1 0.2
0.40 0.60 0.41 (0.35, 0.47) 0.42 (0.36,0.47)
0.50 0.60 0.41 (0.34, 0.47) – –
0.3 0.3
0.40 0.60 0.51 (0.48, 0.54) 0.52 (0.48, 0.55)
0.50 0.60 0.51 (0.48, 0.54) 0.51 (0.48, 0.54)
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Table 4.12: Summary of Allocation Rate (IQR) at the
75th Percentile Visit for Trt A (Clayton Copula)
Primary Auxiliary Sample Variance
trtA trtB trtA trtB γ=2 γ=8
0.1 0.3
0.40 0.60 0.37 (0.32, 0.40) 0.38 (0.33, 0.41)
0.50 0.60 0.37 (0.32, 0.41) 0.37 (0.32, 0.41)
0.1 0.2
0.40 0.60 0.41 (0.36, 0.46) 0.42 (0.37, 0.46)
0.50 0.60 0.41 (0.36, 0.46) – –
0.3 0.3
0.40 0.60 0.51 (0.48, 0.54) 0.52 (0.49, 0.54)
0.50 0.60 0.51 (0.48, 0.54) 0.51 (0.49, 0.54)
Chapter 5
Discussion and Future Work
Discussion
Using both primary and auxiliary outcomes provides us an alternative adaptive allocation
method, where we attempt to shift the probability of allocation toward assigning more
patients to the ”better” treatment when a primary outcome can not be rapidly collected.
The adaptive design method is derived from the minimization of a specified loss func-
tion with constraints on the variability of each adaptive stage, where the loss function
is a linear combination of weights and number of patients in each treatment group. The
traditional adaptive design has the weight related to primary efficacy. Therefore, we pro-
posed a statistical model to connect auxiliary and primary outcomes and calculate the
posterior conditional expectation of primary efficacy (P2, which is parameter of interest),
given auxiliary efficacy (P1). We then substitute conditional expectations as the weights
on the treatment groups. The most promising advantage of this modeling is that we allow
the adaptive allocation without neglecting information of primary outcome, which allows
quicker adaptation through the use of the auxiliary outcome.
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The two-dimensional Bayesian model is complicated, in the terms of prior selection and
model fitting. The first statistical model presented is based on the two dimensional beta-
binomial distribution to describe the correlated auxiliary and primary outcome data.
We studied the performance of a three-parameter bivariate beta distribution (Olkin and
Liu, 2003) and a Morgenstern type five-parameter bivariate beta distribution with fixed
marginal distributions. We noted that the three-parameter bivariate beta distribution
does not allow correlation to range freely between [−1, 1] when the marginals are fixed.
If both marginal means are small, the correlation of the marginal is negligible or weak.
As both marginal probabilities increase, the correlation falls in range from moderate
to strong. Compared with the three-parameter bivariate beta distribution, the five-
parameter bivariate beta distribution is even more restrictive on the correlation, where
the maximum absolute correlation is 1
3
. In general, the three-parameter bivariate beta
distribution is a better choice as prior for its simplicity and flexibility.
We ran a simulation study using the proposed statistical model with the three-parameter
bivariate beta prior distribution. The purpose of the simulation is to see how the bivariate
adaptive method performs when the prior correlation information is different from that
which the simulated data is based on. In this study, we focused on particular cases where
the primary outcome is a rare event and in delay, where the probability varies from 0.1
to 0.3. The auxiliary outcome is a short-term response and can be collected relatively
quicker (at least quicker than patient enrollment), where its probability ranges from 0.4
to 0.7. Compared with the univariate optimal adaptive design, the bivariate optimal
adaptive design assigns more patients to the better treatment and reduces patient deaths
by 1 or 2 when a treatment difference exists, while maintaining similar power and error
rates. As we have seen, the advantage of the bivariate optimal method lies in the practi-
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cal clinical scenarios, especially for survival studies (e.g. cancer studies) where complete
remission is the primary endpoint. It seems that the auxiliary efficacy difference does
not affect the simulation results as long as the auxiliary efficacy difference has the same
direction of the treatment difference. The similarity might be a result of weak correlation
between auxiliary and primary efficacies when primary efficacies are relatively small.
We therefore introduced copula-based bivariate distributions to our statistical model.
The copula method allows us to separately model marginal distributions and the depen-
dence structure of the joint distribution. And we are also able to compare the results of
bivariate optimal adaptive method when the association of auxiliary and primary out-
comes is moderate and strong. The choice of the copula is important and difficult. On
one hand, all information about the dependence structure is contained in the copula
function. On the other hand, no systematic method guarantees the selected copula to
approximate the real dependence structure. We first studied the Gaussian copula, due to
its simplicity, to construct the joint bivariate distribution. We then also applied the Clay-
ton copula to the proposed model, based on the characteristics of clinical scenarios which
require high dependence between correlated small events data. Comparing both results,
we have noticed that the allocation rates using the Clayton copula favors the ”better”
treatment more consistently than that using the Gaussian copula. In other words, the
IQR of the allocation rate using the Clayton copula is much wider than that of using
Gaussian copula, even though the medians are equivalent. This leads to the phenomena
that the expected number of patient failures is comparable using both copulas but the
standard deviation using the clayton copula is slightly larger than that of using Gaussian
copula.
The copula-based prior gives us the flexibility to model the dependence of correlated
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data free of specified marginal distributions, even though the simulated adaptation re-
sults using the copula-based prior and the three-parameter bivariate beta distribution
are similar. The copula-based prior also makes the bivariate optimal adaptive method
more applicable to a clinical trial study in practice, where we take advantage of historical
information of the endpoints to modify marginal distributions of priors as well as the
dependence structure. Our proposed method is suitable for the clinical scenario when
the delay in response in not stochastic and the endpoints take a long time to observe.
Future work
In this study, we fixed the number of delayed patient to be 30, meaning the primary
response becomes available when there are 30 patients enrolled in the trial, which does
not reflect real clinical trial setting, though it does accurately reflect a delayed response.
The delayed response depends on response time and treatment assignment. For instance,
the delay in responses will be longer for the inferior treatment group which has smaller
efficacy. Therefore, to model the delayed response for each treatment following parametric
distribution (e.g. exponential distribution) would be more appropriate and promising.
Meanwhile, it is common in long-term clinical trials to encounter the presence of censoring,
such as patient death or loss follow-up. The consideration of censoring in the simulation of
delayed primary responses is important to study the performance of the bivariate optimal
design.
It is important and challenging to make a right choice of copula for the bivariate joint
distribution that suits for describing the dependence of auxiliary and primary outcomes.
In this study, we only chose the Gaussian and Clayton copulas to be the representatives for
empirical copulas and Archimedean copulas. In the future, we may explore other copulas
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such as student t copula, frank copula, etc. to construct the joint bivariate distribution
with marginal beta distributions. To make our results comparable with the model using
the bivariate beta distribution, we choose to apply a joint copula-based prior instead
of using copula method to model joint distribution of primary and auxiliary outcomes.
Other future work may involve jointly modeling the likelihood using copula method and
have independent priors for the bivariate optimal adaptive design. In the earlier chapters,
we have mentioned that the concurrent bivariate binomial distributions are not an idea
choice to be the likelihood for the positively correlated binomial random variables. Using
copula methods, we are able to overcome the limitation of the existing bivariate binomial
distribution on the correlation.
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